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CHAPTER 1 
 
INTRODUCTION 
 
Arrestins and G protein-coupled receptors 
 G protein-coupled receptors (GPCRs) are the largest superfamily of proteins with 
approximately 1000 known members in the human genome (1).  They are activated by a 
variety of different ligands such as light, calcium ions, odorants, small molecules, protein 
hormones, extra-cellular proteases, etc.  With such a wide array of stimulants, it is 
unsurprising GPCRs mediate many processes including neurotransmission, olfactory, 
immune, and hormone responses, chemotaxis, and vision.  Despite extensive diversity 
amongst family members, GPCRs share many of the same structural and functional 
characteristics.  First, they are composed of 7-transmembrane helical structures, with an 
external N-terminal region, and an intracellular C-terminus (2).  Their principal function 
is to transmit information from the extracellular environment to the inside of the cell to 
promote a signaling response.   Upon ligand binding, GPCRs undergo a conformational 
change that promotes binding to heterotrimeric GTP-binding proteins (G proteins).  
Engagement with the receptor leads to an exchange of GDP for GTP on the α subunit of 
the G protein, causing it to disengage from the receptor and dissociate into Gα and 
Gβsubunits (3)These G protein subunits  amplify GPCR signals by activating a wide 
variety of effector proteins such as adenylate cyclase, phosphodiesterases, Ca
2+
 or K
+
 
channels, and phosopholipases.   
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 After G protein activation and subsequent signal amplification it becomes 
imperative that signal transduction cascades be shut down.  Cells have developed an 
adaptive response through receptor desensitization, which prevents harmful effects 
caused by constant receptor stimulation.  There are two types of receptor desensitization. 
Second-messenger-regulated kinases, PKA (protein kinase A) and PKC (protein kinase 
C), can phosphorylate both active and inactive GPCRs leading to “heterologous” 
desensitization (4).  G protein-coupled receptor kinases (GRKs) on the other hand are 
serine/threonine kinases that only phosphorylate agonist-stimulated receptors, resulting in 
“homologous” desensitization.  Seven mammalian GRK genes have been identified 
(GRK1-GRK7) (3).  Receptor desensitization by GRKs occurs by a two-step process.  
First, GRKs phosphorylate the serines and threonines on the C-terminus or other 
cytoplasmic elements of the receptor.  Second, when the number of receptor-attached 
phosphates reaches a threshold (usually 2 or 3), arrestin recognizes the active 
phosphorylated receptor and binds with high affinity, ultimately precluding further G 
protein activation (5).  
The stable binding of arrestin is the terminal step in G protein-mediated receptor 
signaling: the receptor is unable to respond to additional ligand unless it has been re-
sensitized. The receptor must be desensitized, internalized, dephosphorylated, and 
recycled back to the plasma membrane to become responsive again.  Arrestins’ role in 
this process became clear when studies showed that arrestins interact with clathrin, and 
the expression of mutant arrestins that do not bind β2-adrenergic receptor or clathrin 
reduced receptor endocytosis.  It was later shown that arrestins bind with high affinity to 
clathrin (6) and adaptor protein AP2 (7) and that receptor-bound arrestin serves as an link 
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between receptors and clathrin coated pit formation (Figure 1-1) (8).  The receptor is then 
internalized to endosomes, dephosphorylated, and recycled back to the plasma membrane 
for further activation (9, 10).  In some cases, receptors are targeted for lysosomes where 
they are degraded. 
 
The Arrestin family of proteins 
There are 4 known arrestin subtypes, two visual arrestins, arrestin-1 and arrestin-4 
which are expressed exclusively in rod and cone photoreceptors, and two non-visual 
arrestins, arrestin-2 and arrestin-3, which are ubiquitously expressed.  The first arrestin 
discovered, arrestin-1, was shown to bind GPCR rhodopsin and influence light dependent 
signaling in rod photoreceptors (11-14).  Because arrestins first known function was to 
terminate rhodopsin signaling, its name is derived from its ability to "arrest" further G-
protein activation.  One other retinal-specific arrestin was cloned, arrestin-4, which shows 
~50% homology to arrestin-1 and is found predominantly in cone photoreceptors 
(whereas arrestin-1 is found in both rod and cone photoreceptors) (15).   
Like the visual arrestins, the non-visual arrestins were discovered in the early 90’s 
to bind the β-adrenergic G protein coupled receptor.  Their original names, β-arrestin-1 
and β-arrestin-2, were chosen because of their preference for β-adrenergic receptors over 
rhodopsin (16).  It was later discovered that unlike their visual counterparts, that have 
preference for only rhodopsin (arrestin-1) or cone opsins (arrestin-4), the non-visual 
arrestins have broad receptor specificity and are capable of binding to hundreds of 
different GPCRs.  Therefore, they were later renamed arrestin-2 and arrestin-3. Arrestin-2 
is the predominant arrestin expressed in most tissue types (17), with arrestin-3  the  
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Fig. 1-1.  The ‘‘classical’’ model of arrestin-mediated GPCR desensitization.  
The agonist-activated receptor activates cognate heterotrimeric G proteins that 
subsequently stimulate various signaling cascades increasing the activity of protein 
kinases PKA, PKC, etc. Active receptor is specifically phosphorylated by GRKs. Arrestin 
binds the active phosphoreceptor with high affinity, precluding further G protein 
activation. Arrestin serves as an adaptor linking the receptor to the internalization 
machinery of the coated pit (clathrin, adaptor complex AP-2), facilitating receptor 
internalization. Low pH in the endosome promotes agonist dissociation, which facilitates 
the release of arrestin, whereupon the receptor can be dephosphorylated and recycled 
back to the plasma membrane (resensitization). Alternatively, the receptor can be 
transported to lysosomes and destroyed (down-regulation). (Adapted from (18))  
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predominant form in olfactory epithelium (19).   In addition to differences in expression 
level, they demonstrate certain receptor specificity, have different affinities for clathrin, 
and differentially activate MAP kinase cascades.  For example, both arrestin-2 and 
arrestin-3 are able to bind the kinases of JNK3 activation cascade, but only when bound 
to arrestin-3 is JNK3 activated (20).  However, despite functional differences, they are 
able to compensate if one or the other arrestin is knocked down.  Mice lacking either 
arrestin-2 or arrestin-3 show no overt abnormalities and very small differences in 
phenotype, however, knock-out of both proteins is embryonic lethal (21).  This finding is 
not surprising, the non-visual arrestins share 78% identical amino acid sequence and 
remarkable structural homology (22). 
 
Arrestin structure and binding 
Structurally arrestins are elongated two-domain (the N- and the C-domain) 
molecules with a tertiary structure that is conserved between all four subtypes (23). 
Arrestin is maintained in its cytosolic free state by two intra-molecular interactions.  The 
first is a series of charged residues called the ‘polar core’ that bridge the domains of the 
protein.  The second involves interaction between β-strand-1 and α-helix-1 of the N-
domain, and the C-tail of the protein (three element interaction).  Receptor binding 
disrupts both these interactions, causing a distinct conformational change in arrestin 
(Figure 1-2a).  The ‘polar core’ acts as a phosphate sensor, and interaction with 
phosphorylated receptor breaks the bridge between the two domains, allowing arrestin to 
bind with high affinity (24, 25).   Disruption of the three element interaction results in the 
release of the C-tail from the body of the protein.  Upon release of these two critical  
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Figure 1-2.  The conformation of receptor bound arrestin 
(A)  Arrestin undergoes a major conformational change upon binding to GPCRs.  (B) The 
hinge region is colored in yellow. Residues 179 and 191 denote the borders of the hinge. 
The distance indicated by the line is measured from the Cα of residue 179 to the Cα of 
residue 190. The hashed blue section represents a crystallographically disordered part of 
the polypeptide.  (C) The P-Rh* binding of 24 mutants with various deletions in the 
hinge region was analyzed as a function of the total number of deleted residues. The 
correlation was found to be statistically significant (r = 0.91, F(1,23) = 107;p < 0.0001). 
(Adapted from (26))  
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“clasps” that hold the protein in its free cytosolic state, the two domains of the protein are 
free to move relative to each other (27).   
To ensure proper domain movement, a large amount of flexibility between the 
two domains must be present. Indeed arrestin has a 12 amino acid inter-domain 
connector, or hinge region, that makes this movement possible (28) (Figure 1-2b). 
Interestingly, the number of amino acids required to span the two domains is only five, 
suggesting that the additional amino acids provide flexibility through substantial ‘slack’ 
(29-31) .  Additionally the hinge region has several conserved residues, all of which are 
prolines, glycines, and alanines further implicating the importance of flexibility.  
Successive deletions of this hinge region show that receptor binding is completely 
abolished when seven amino acids are removed, i.e., when the hinge is just long enough 
to cover the distance between the two domains (Figure 1-2c).   
 
Arrestins as signaling scaffolds 
 Shortly after the discovery that arrestins bind to GPCRs and terminate their 
signaling, a variety of additional binding partners were discovered.  AP2 and clathrin 
were among the first, and their binding sites were localized to arrestins C-tail.  
Furthermore, the release of the C-tail from the body of arrestin upon interaction with the 
receptor promotes AP2 and clathrin binding.  Another interaction partner, c-Src, was also 
shown to be recruited to receptor-rich membranes in an arrestin dependent manner, 
resulting in the spatially controlled activation of extracellular signal-regulated kinases 
(ERK1/2) (32). The fact that several proteins, including clathrin, AP2, c-Src, and ERK 
preferentially bind activated arrestin (i.e. interact with the arrestin-receptor complex) (33) 
8 
 
suggests that the conformations of free and receptor-bound arrestin are dramatically 
different.  Additionally it implicates arrestin as an adaptor to redirect GPCR signaling by 
linking signaling proteins to the receptor.  Consistent with this, receptor binding elements 
were found to be limited to the concave sides of both arrestin domains, leaving the 
backside of the molecule exposed for interactions with other proteins (Figure 1-3).   
Over the years the number of additional binding partners has rapidly increased.  
These include ARF6, ARNO, PDE4, NSF, Mdm2, IB, calmodulin, and a variety of 
protein kinases, such as Yes, cRaf1, JNK3, and ASK1 (reviewed in (34)).  A majority of 
these proteins were also originally shown to have preference for receptor-bound arrestin, 
with a few exceptions.   Calmodulin, was shown to bind the C-domain and a loop in the 
center of the arrestin molecule (35).  These binding sites significantly overlap with 
receptor binding elements, suggesting arrestin interactions with GPCRs and calmodulin 
are mutually exclusive (Figure 1-3). 
However, several recent studies have shown that the interactions of arrestin with 
its non-receptor binding partners are not so black and white. For example, the binding 
sites for PDE4 (36) and ARF6 (37) are exposed on either receptor-bound or free arrestin, 
allowing these proteins to bind either state.  Additionally, ubiquitin ligase Mdm2 has 
higher affinity for arrestin in its free conformation. However, the receptor-arrestin 
complex is likely a better substrate for Mdm2, the level of arrestin ubiqutination by 
Mdm2 is proportional to the stability of the receptor-arrestin complex (38).  This suggests 
that free arrestin in the basal conformation binds Mdm2, brings it to the receptor, and 
releases it upon receptor binding (39).  
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Figure 1-3. Conformational dependence of arrestin interactions with signaling 
proteins.   Although the effect of arrestin conformation on the binding of the majority of 
arrestin partners remains to be elucidated, differential interactions of several proteins with 
free and receptor-bound arrestin have been demonstrated. Clathrin and AP2 preferentially 
bind receptor-associated arrestin via its released C-tail; it is not known whether 
microtubule binding-induced C-tail release has similar effect. Calmodulin binding site 
includes the elements involved in receptor and microtubule interaction, so that it can only 
bind free arrestin. Ubiquitin ligase Mdm2 binds all forms of arrestin, but apparently has 
lower affinity for the receptor-bound state. JNK3 binds free and receptor-bound arrestin. 
Note that in real life receptor-bound arrestin cannot simultaneously interact with all the 
partners shown here.  (Adapted from (40))  
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One of the most well studied arrestin scaffolds underscores the complexity of arrestin 
signaling. Arrestin-2 and arrestin-3 were first reported to scaffold c-Jun NH2-terminal 
kinase3 (JNK3) (41), ERK1/2 (42, 43), and p38 (44) MAP kinase activation cascades in a 
complex with different receptors.  These cascades consist of three different kinases 
MAPKKK (such as Raf1), MAPKK (such as MEK), and MAPK (such as ERK1/2).  Each 
kinase is activated by phosphorylation by the kinase that precedes it in the cascade (45).  
How these proteins are able to come into close quarters to each other for activation with 
any specificity is determined by scaffolding proteins that link the proteins together into a 
signaling module.  Arrestin serves as a link for the proteins in these cascades, and the 
complexity of these interactions is only growing.      
Initial data showed that JNK3 binds arrestin-3, but not arrestin-2, in a receptor-
dependent manner. Activation of angiotensin 1A receptor (AT1AR) leads to arrestin-3-
dependent recruitment to the plasma membrane and subsequent activation of JNK3. 
Additionally, only arrestin-3 was shown to be responsive to receptor activation in this 
system, with arrestin-2 showing a dominant negative role in regulating JNK3 activity 
(46).  However, later studies showed that JNK3 binding is not limited to arrestin-3.  All 
four arrestin subtypes bind all members of the JNK3 cascade (ASK1, MKK4, JNK3) with 
comparable affinity (20).  Only arrestin-3 was able to activate JNK3, proving that JNK3 
binding to arrestin does not necessarily translate into activation.  This finding partially 
explains the dominant-negative role of arrestin-2, where arrestin-2 is capable of binding 
JNK3 and keeps it in its inactive form.  Moreover, an arrestin-3 hinge deletion mutant 
that is deficient in receptor binding was also capable of activating JNK3, proving that 
receptor interaction is not required (20). The fact that only arrestin-3 is capable of 
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activating JNK3, and that receptor interaction is not required, suggests that arrestin-3 is 
capable of holding ASK1, MKK4, and JNK3 in a particular configuration that promotes 
signal transduction (20).  If this is the case, JNK3 activation likely involves only a few 
key residues on arrestin-3 due to the significant homology between the arrestin proteins.  
Indeed, multiple residues on the non-receptor binding surface of arrestin were found to be 
crucial in JNK3 activation (47).  These studies showed that arrestin-3 can bind and 
activate JNK3 in both a receptor-dependent, and a receptor-independent manner. 
One function of JNK3 is to translocate to the nucleus to phosphorylate various 
transcription factors such as ATF2 and members of the Jun family (45). To further 
complicate how and when arrestins bind to JNK3, the non-visual arrestins were shown to 
shuttle between the nucleus and the cytoplasm (48).  Arrestin-3 has a functional nuclear 
export signal (NES) in its C-terminus and is capable of removing JNK3 from the nucleus 
to the cytoplasm (48, 49).  Additionally, all free arrestins are able to bind JNK3 with high 
enough affinity to bring it out of the nucleus and dramatically change its subcellular 
localization (39), most likely to regulate transcription in the nucleus.  Thus arrestins 
regulate JNK3 activity at the receptor, in the cytoplasm, and in the nucleus.    
These data taken together show that arrestin-3 can activate JNK3 regardless of its 
conformation under different conditions (receptor-specific, and receptor-independent 
activation) and for different functions (Figure 1-3).  However, how arrestins decide when 
and how to scaffold certain MAP kinase cascades largely remains a mystery. 
 The ability of arrestins to scaffold a variety of different proteins under a broad 
range of conditions underscores the wide diversity of its function, and the momentum of 
new discoveries is only gaining.  New functions are being discovered for “old” signaling 
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partners such as ERK1/2 and many new interaction partners are still being discovered.  
One area of research where arrestins are significantly gaining territory is in the regulation 
of cytoskeletal-mediated events (50-53).    
 
Arrestins regulate proteins involved in cytoskeletal rearrangement 
 With the growing interest in the ways cells sense chemical gradients in the 
environment around them, investigators hypothesized that arrestins play a role in directed 
migration.  First, as the cell migrates the signaling must be quenched at the trailing edge 
of the cell.  The role of arrestin in receptor desensitization and signal termination made 
them perfect candidates to facilitate this process.  Secondly, migration requires the 
coordinated activation of hundreds of proteins in distinct spatial regions of the cell (54).  
Because arrestins are well known scaffolding proteins capable of generating their own 
signals and localizing proteins to distinct regions of the cell, they are also heavily 
suspected to regulate various signaling proteins involved in generating the forces that 
promote movement.    
Arrestins regulate chemokine-mediated migration 
Chemotaxis is the phenomenon in which cells direct their movements according 
to certain chemicals in their environment.  This process requires an external chemical 
ligand interacting with a cell-surface receptor, a coordinated signaling response that leads 
to cytoskeletal rearrangement, cell polarization, and subsequent motility in the direction 
of the chemoattractant (55, 56).  Two defining processes make chemotaxis possible. The 
formation of the leading edge, which provides the force to drive directed migration, and 
de-adhesion of the trailing edge, which allows the cell to move forward.  These processes 
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are largely mediated by chemokine receptors, GPCRs that respond to chemokines 
released by sites of injury or inflammation (57). There are several families of chemokine 
receptors, each having several members. Two major families are the CXC family of 
chemokine receptors (CXCR1-7), activated by different CXC ligands, and CC chemokine 
receptors (CCR1-10), each responding to a variety of different CC ligands.  These 
receptors are found in a variety of cell types (some have wide distribution, some are cell 
type specific, e.g., found only on B or T lymphocytes) (57). The first demonstration that 
arrestins were required for chemotaxis showed that CXCR4-mediated lymphocyte 
chemotaxis was defective in cells lacking either arrestin-3 or GRK6 (58).  Shortly after, 
arrestins were implicated in a variety of other chemotactic events involving CXCR1, 
CXCR2, CXCR3, and CCR5, although the exact mechanisms are not known (59-61). 
 The role of arrestins as mediators of receptor endocytosis led investigators to 
hypothesize that arrestin-dependent desensitization of chemokine receptors is key to 
chemotaxis.  Indeed, arrestin co-localization studies showed arrestins associate with 
chemokine receptors, but the relationship between these two proteins is complex.  All of 
the experiments conducted to examine arrestin-dependent receptor desensitization were 
done in different cell types with different ligands, most of which resulted in different 
outcomes.  For example, one study clearly showed that a chimera of CXCR1 and CXCR2 
was unable to bind arrestin-3 and failed to internalize.  However, chemotaxis was 
unaffected, suggesting that internalization is not essential for this process (62).  
Conversely, other studies showed that arrestin-dependent internalization is required; both 
CXCR1 and CXCR2 when treated with either a dominant-negative arrestin (which is 
unable to target receptors for clathrin coated pit formation), or when the C-terminal 
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phosphate sites required for arrestin binding were removed, showed defects in both 
internalization and chemotaxis (63).  Other reports showed that when a single amino acid 
of the second intracellular loop of CCR5 required for arrestin-dependent chemotaxis was 
mutated, the receptor still underwent ligand-induced endocytosis but chemotaxis was 
inhibited (60, 64).  These data suggest that the chemokine response systems are quite 
complex.   
One study in particular highlights the complexity of chemokine receptor 
signaling.  CXCR3, which is activated by three ligands (CXCL9, -10, -11), can produce 
dramatically different outcomes based on the ligand and the conditions.  For example, 
activation by CXCL11 results in higher level of internalization than CXCL9 or -10.  
Additionally, chemotaxis as a result of treatment of cells with high levels of CXCL9 and 
CXCL11 but not CXCL10 requires residues in the third intracellular loop of the receptor. 
Conversely, the C-terminus of the receptor is required for chemotaxis when cells are 
treated with CXCL10 and CXCL9, but not CXCL11.  These data show that different 
components of the receptor are used in ligand-biased ways, where CXCL10 and CXCL9 
predominantly induce a pathway dependent on the receptor C-terminus, and CXCL11 
predominantly promotes signaling initiated by other elements of the receptor. 
Additionally, the concentrations of these ligands also play a role in determining the 
outcome of chemokine receptor signaling as evidenced by the different pathways 
activated by treatment with either high or low levels of CXCL9 (65). 
 Data showing that internalization is not required for chemotaxis for some 
receptors, or that arrestin-dependent chemotaxis was inhibited even when some receptors 
were internalized suggests that arrestins play a role beyond mediating endocytosis.  
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Arrestins also act as signaling scaffolds for a variety of cytoskeletal regulatory proteins, 
and are capable of localizing them to particular compartments of the cell, or scaffolding 
them for activation. 
Arrestins as regulators of the small GTPases 
 There is growing evidence for a role of the non-visual arrestins in facilitating 
small GTPase-mediated events.  Rho family GTPases are small G proteins that act as 
bimolecular switches that regulate the signal transduction pathways that connect the 
plasma membrane receptors to the cytoskeleton of the cell (66). The three most 
characterized Rho GTPases are RhoA which promotes stress fiber formation, Rac1, 
important for membrane ruffling and lamellipodia, and Cdc42 a well-known inducer of 
filopodia formation (67, 68). They regulate many important cellular processes that range 
from cytoskeletal rearrangement, gene expression, membrane trafficking, and are 
essential for motility in most systems (69).  The first study to link arrestins to RhoA 
activity showed that RhoA is coordinately activated by arrestin-2 and Gαq/G11 upon 
activation of the Angiotensin II type 1A receptor (ATII1AR).  This leads to stress fiber 
formation mediated through Rho-associated protein kinase. Knock-down of either 
Gαq/G11 or arrestin-2 (but not arrestin-3) significantly reduces RhoA activity (70). 
However, the precise mechanism through which arrestin-2 and Gαq/G11 activate RhoA 
in a concerted manner was not addressed. However, both direct and indirect mechanisms 
by which arrestins regulate RhoA activity were later described.   
First, arrestin-3 was shown to directly bind RhoA in Xenopus embryos. The 
movement of cells in gastrulation and axis formation are critical for vertebrate 
development.  Depletion of Xenopus arrestin-3 (xArr3) in embryos resulted in major 
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developmental defects in convergent extension (CE), a process that involves cell 
migration to define and extend the antieror/posterior axis.  In particular, loss of xArr3 
results in delay of blastopore closure, failure of neural tube closure and anterior/posterior 
axis formation.  These defects resemble those caused by altered signaling of Wnt 
pathway components, including downstream protein RhoA (71).  Experiments to 
determine whether RhoA is involved in the xArr3 specific defects demonstrated that 
xArr3 binds directly to RhoA, resulting in its recruitment and accumulation at the plasma 
membrane.  In addition, xArr3 also bound to Daam1, a formin homology (FH) protein 
involved in scaffolding and activating RhoA. Daam1-RhoA-xArr3 interaction resulted in 
the activation of RhoA and regulation of CE movements at the plasma membrane (72). 
The key feature of the small GTPases is the ability to switch between inactive and 
active forms.  To achieve this balance, they interact with three types of regulatory proteins: 
guanine nucleotide exchange factors (GEFs), which exchange GDP for GTP to render small 
G proteins active, guanine nucleotide dissociation inhibitors (GDIs), a regulatory protein that 
prevents GDP/GTP exchange and inhibits membrane localization, and GTPase-activating 
proteins (GAPs), which accelerate the GTPase activity and promote hydrolysis of GTP to 
inactivate the small G protein (73).  Arrestin-2 but not arrestin-3 was shown to indirectly 
regulate RhoA activity by direct interaction with ARHGAP21, a GAP protein known to 
localize to the Golgi apparatus were it can act as a GAP for RhoA, Rac1, and Cdc42.  
Importantly, arrestin-2 binds directly with GAP domain of the protein: the interface that 
interacts with RhoA to accelerate hydrolysis of GTP.   Arrestin-2 binding essentially inhibits 
the interaction of ARHGAP21 with RhoA, resulting in prolonged RhoA activity.  Direct 
disruption of the ARHGAP-Arrestin-2 complex results in more active ARHGAP21, and less 
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RhoA activity.  Interestingly, this complex is not dependent on receptor activation, however, 
the concentration of the ARHGAP21-Arrestin-2 complex increases upon activation of the 
AT1AR receptor (74).  The mechanism is not well known, however it is proposed that the 
conformation of receptor-bound arrestin may bind ARHGAP21 with higher affinity. 
Arrestin was also shown to interact with another, less studied, GTPase.  Under basal 
conditions, inactive Ral-GDS is localized within the cytosol of the cell as a result of 
interaction with cytosolic arrestin-2.  Upon fMet-Leu-Phe receptor (fMLP) stimulation, 
arrestin translocates to the plasma membrane, bringing Ral-GDS within the proximity of 
RalA.  Disruption of the Ral-GDS-arrestin interaction results in Ral-GDS activation of the 
Ral effector pathway and subsequent membrane ruffling (75).  Depletion of arrestin-2 in 
these cells inhibits Ral-mediated membrane ruffling.  While arrestin interaction does not 
result in activation of these proteins, this study underscores the importance of arrestin as a 
shuttle for proper localization of signaling proteins.   
The role of arrestins in actin assembly 
Recent investigations show that arrestins act as a scaffold for proteins involved in 
actin assembly.  Cofilin is an actin filament-severing protein that causes 
depolymerization at the minus ends of actin filaments by creating positive ends, a process 
that is tightly regulated spatially and temporally.  Cofilin is regulated by a recently 
identified cofilin-specific phosphatase, chronophin (CIN), that dephosphorylates residue 
Ser3 resulting in its activation.  Conversely, phosphorylation at this site by LIM kinase 
(LIMK) renders cofilin inactive (76, 77).  Because cell migration involves rapid turnover 
and formation of protrusions at the leading edge of the cell, the non-visual arrestins were 
prime candidates to localize cofilin to its site of action at the plasma membrane.  Indeed, 
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it was shown that arrestin-2 and arrestin-3 bind all three proteins: cofilin, chronophin, and 
its inhibitor LIMK, and recruit them to the leading edge of the cell upon PAR-2 receptor 
stimulation.  The result of this scaffold leads to arrestin-dependent activation of cofilin 
(78).  Conversely, knock-down of arrestin through siRNA showed that PAR-2 
stimulation led to an increase in LIMK activity, suggesting that arrestin may bind LIMK 
to “keep it away” from the phosphorylation site on cofilin to prevent its deactivation. 
Therefore, the scaffold has three essential functions: 1) To localize cofilin to 
compartments of the cell where it can modify the actin cytoskeleton to create membrane 
protrusions, 2) bring cofilin in proximity to its activating protein, cronophin, leading to its 
activation, and 3) recruits LIMK to possibly “dock” it away from cofilin to prevent its 
deactivation.  Interestingly, while PAR-2 induced cofilin dephosphorylation and filament 
severing can be mediated by either arrestin, arrestin-3 was found to colocalize with 
cofilin predominantly in the back of F-actin-rich protrusions, and arrestin-2 was 
predominantly found at the tips.  Additionally, arrestin-2 associated with CIN within 5 
minutes of PAR-2 stimulation but arrestin-3 could not be co-immunoprecipitated with 
CIN.  This suggests a role for arrestins in regulating the spatial restriction of cofilin 
activity, and that the role of arrestin-2 and arrestin-3 in mediating actin filament severing 
is different. 
Receptor desensitization meets cytoskeletal organization 
ARNO (Arf nucleotide binding site opener) has been reported to interact with the 
non-visual arrestins to regulate receptor desensitization (79).  ARNO is also a GEF for 
ARF6 (ADP-ribosylating factor 6) which couples to the cytoskeleton via ELMO 
(engulfment and cell motility protein) to regulate lamellipoda formation and cell 
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migration (80).  Arrestin acts as a scaffolding protein for the ARNO-Arf6-ELMO 
signaling network, which is activated upon stimulation of the calcium-sensing receptor 
(CaSR) in an arrestin-dependent manner (81). This suggests that arrestins localize these 
proteins to the receptor for activation, while also promoting endocytosis through an 
ARNO dependent mechanism. With this model it is easy to imagine a scenario where 
arrestins bring regulatory proteins to the leading edge to promote cytoskeleton 
rearrangement, while also desensitizing receptors to facilitate gradient sensing.   
Arrestins and cancer 
Recently it has been reported that arrestin-3 acts as a scaffold protein in mitogen-
activated protein kinase (MAPK) cascades that positively regulate chemotaxis.  Arrestin-
3 depletion promotes CXCR2-mediated cellular signaling, including excisional wound 
closure and angiogenesis.  To further investigate the role of arrestin-3 in tumorigenesis, a 
murine model of lung cancer was used to compare arrestin-3-deficient mice (Arr3-/-), and 
control littermates (Arr3+/+).  In mice deficient in arrestin-3, tumor growth occurred 3.2-
fold faster as compared with littermate controls.  Additionally, the number of metastatic 
lung nodules in Arr3-/- mice was significantly greater; with ~5.66-fold higher 
colonization in the lungs relative to wild-type animals.  In addition, tumor infiltrates form 
Arr3-/- deficient mice showed a significant decrease in NK+ cells, CD3+, CD4+, and 
CD8+ lymphocytes relative to Arr3+/+ mice (61).  Whether or not this decrease in T cell 
infiltration contributes to the significant increase in tumor development and metastasis is 
unclear. 
 It is clear that arrestins regulate the cytoskeletal proteins on many levels.  They 
desensitize and internalize chemokine receptors so they can be recycled back to the 
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plasma membrane to promote continual gradient sensing.  Arrestins also act as shuttling 
proteins that localize cytoskeleton associated proteins to the plasma membrane such Ral-
GDS or the ARNO/Arf6 complex.  They assemble regulatory proteins with their 
activation proteins, such as RhoA and Daam1, or cofilin with chronophin, leading to their 
activation. All of these studies implicate arrestins as indirect regulators of the 
cytoskeleton, however, recent studies show that arrestins may play a more direct role.  
The first indication of this was the discovery that visual arrestin-1 binds directly to the 
cytoskeleton in the visual system.  Because arrestins bind to and recruit a vast array of 
signaling proteins, this interaction could potentially result in many functional outcomes.    
 
Arrestins bind directly to the cytoskeleton 
Arrestin-1 function and translocation in rod photoreceptors 
 The best characterized signaling proteins for any GPCR-mediated signaling 
pathway are involved in vertebrate phototransduction.  They include rhodopsin, the 
GPCR responsible for light detection, transducin, the visual G protein, and rhodopsin 
kinase (GRK1).  All players in this cascade have served as structural and functional 
models for their non-visual counterparts.  Upon activation by light, 11-cis-retinal 
covalently linked to rhodopsin is photoisomerized to all-trans-retinal, rendering 
rhodopsin active (R*).  R* causes the rapid exchange of GDP for GTP on the G protein 
transducin, thus propagating the phototransduction cascade.  Because rods demonstrate 
single photon sensitivity, the shut-off mechanism for rhodopsin must maintain high 
temporal resolution and sub-second kinetics (82-84).  To this end, rhodopsin is 
desensitized in a two-step mechanism.  The first step occurs when a specific kinase, 
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GRK1, recognizes the activated receptor and phosphorylates its C-tail.  When the number 
of phosphates reaches three (P-Rh*) (85, 86), arrestin-1 binds the receptor with high 
affinity, thereby sterically precluding transducin from further interaction with rhodopsin 
(87, 88). P-Rh* subsequently decays to phosphoopsin, loses all-trans-retinal, is 
reconstituted with 11-cis-retinal produced by the retinal pigment epithelium, and is 
dephosphorylated.  Ultimately, these processes regenerate the inactive state of Rh that 
does not bind transducin or arrestin with appreciable affinity.   
Even though rhodopsin activation and termination serves as a model for nearly all 
GPCRs, photoreceptor signaling is unique in many ways.   Rod photoreceptors are 
polarized elongated neurons that are comprised of an outer segment (OS) where 
rhodopsin, transducin, and GRK1 are located, an inner segment (IS) where visual 
arrestin-1 is retained in the dark, a cell body for cell maintenance, and the synapse.  There 
are approximately 1 billion rhodopsins per photoreceptor cell in the OS, implicating the 
massive potential each photoreceptor has to amplify light into electrical signal.  Arrestin-
1 binds rhodopsin at ~1:1 ratio (89, 90),  suggesting that nearly all of the arrestin in the 
photoreceptor (expressed at a similar concentration to rhodopsin) would be required to 
shut down signaling in situations of prolonged illumination.  Since arrestin is kept in the 
IS of the cell in the dark, this would require mass translocation to the OS.  In the dark, 
arrestin is almost completely excluded from the outer segment, whereas it concentrates in 
this compartment in the light (Figure 1-4). Although this massive translocation of arrestin 
from the IS to the OS was described long ago, how it is transported to the OS during 
illumination and how it is retained in the IS in the dark were only recently demonstrated. 
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Figure 1-4. Light-dependent movement of arrestin in rod photoreceptors.  
Arrestin-1 undergoes robust light-dependent translocation, localizing to the OS in the 
light, whereas in dark-adapted rods it is predominantly detected in the IS, perinuclear 
area, and synaptic terminals.  Arrestin-1 binding to P-Rh* necessary for the effective 
photoresponse shutoff occurs within 150ms after the flash or even faster, whereas 
arrestin-1 translocation to the OS happens on the time scale of many minutes.  Thus, 
arrestin-1 already present in the OS is responsible for the termiantion of photoresponse of 
dark-adapted rods.  The estimates of the fraction of arrestin-1 in the OS of WT mice vary 
widely, from 2-9% of the total. 
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 Data clearly show that arrestin translocation occurs by diffusion and is energy 
independent; even when ATP has been depleted from the photoreceptors translocation is 
not affected.  Furthermore, in mice with impaired synthesis of 11-cis-retinal (RPE65
−/−
), 
light does not induce arrestin movement to the OS, indicating that active rhodopsin is 
required for this process (91).  Interestingly, the amount of arrestin-1 that can translocate 
to the OS in the light is limited by the amount of rhodopsin present in this compartment 
(92) indicating that rhodopsin is the binding partner that holds arrestin-1 in the OS in the 
light.  
Arrestin interaction with microtubules 
However, simple diffusion cannot explain why arrestin accumulates in the IS in 
the dark. With diffusion alone, the concentration of arrestin would only equalize in the 
OS and the inner compartments.  However, its precise localization in different light-dark 
states suggests arrestin-1 needs an anchoring mechanism.  Because arrestin does not have 
lipid modifications that restrict it in different compartments, the most likely mechanism 
would involve direct interaction with binding partners.  This interaction partner must be 
sufficiently abundant in the IS, considering the high expression of arrestin in rods (93). 
Importantly, the inner segments of photoreceptor cells are incredibly abundant in 
microtubules, with most polymerized microtubules (MTs) in the axoneme of the cell with 
a much smaller proportion extending into the OS.  Additionally, in an attempt to identify 
arrestin docking proteins by affinity chromatography, tubulin was shown to directly bind 
to arrestins, making it a strong candidate for arrestin localization in the IS (94).  
Additional studies showed that a fraction of arrestin is retained in the dark-adapted OS in 
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amphibian rods, where it colocalizes with the axoneme (95), and arrestin-1 in mouse rods 
was detected near microtubules by electron microscopy (96). 
To investigate whether arrestin binding to microtubules plays a role in its light-
dependent translocation, association of arrestins with cytoskeletal fractions in light- and 
dark-adapted mouse retinas were examined.  Virtually all arrestin in the OS was soluble 
in the light, whereas within 15 min in the dark, a significant proportion of arrestin 
became associated with the cytoskeleton.  This fraction of arrestin remained bound to the 
cytoskeleton for up to 12 hours until light exposure of the dark-adapted mice triggered its 
return to the soluble fraction (97). Additional experiments with purified proteins show 
that microtubules and rhodopsin compete for arrestin binding, suggesting that the 
interactions of arrestin with rhodopsin and microtubules are mutually exclusive (94).   
Given that arrestin is retained in a microtubule rich compartment, that light 
facilitates the release of arrestin from microtubules, and that receptors and microtubules 
compete for receptor binding, microtubules most likely serve as a “default” arrestin 
binding partner, where it is sequestered in the dark and from which it is quickly released. 
Arrestin does not affect tubulin polymerization and microtubule bundling 
To determine whether arrestins affect microtubule function, the rate of tubulin 
polymerization was measured in the presence of arrestin. Interestingly, arrestin had no 
effect on tubulin polymerization.  Additionally, microtubule bundling detected by 
fluorescence microscopy showed no differences in the presence or absence of arrestin-1.  
These data suggest that the primary function of arrestin-1 binding with pre-existing 
microtubules is to localize arrestin in the IS of the cell, and not to regulate microtubules 
(98). 
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All four arrestin subtypes bind microtubules in living cells 
The massive movement of visual arrestin from rod inner segments to the outer 
segments of photoreceptor cells upon rhodopsin activation reveals the importance of its 
proper distribution throughout the cell.  Remarkable structural homology between 
arrestin family members (99) suggests that other arrestin subtypes may also interact with 
MTs.  Cytoskeletal fraction experiments showed that indeed, all arrestin subtypes interact 
with microtubules. In fact, other arrestins bind microtubules better than arrestin-1, with 
arrestin-3 showing the highest binding.   The quantification of soluble and cytoskeleton-
associated arrestins showed that about 2-3 % of wild type arrestin-1, arrestin-4, and 
arrestin-2 are associated with MTs, and this proportion increases to ~8% for arrestin-3 
(Figure 1-5a).  Moreover, both arrestin-2 and arrestin-3 were shown to colocalize to 
microtubules in living cells.   Additionally, truncated arrestin-2, which binds MTs better 
than WT, co-localizes with microtubules to a much greater extent in cells (Fig.1-5b).  
Thus, the association with microtubules in cells is a common characteristic of all arrestin 
subtypes (100).  
 
The conformation and binding sites of microtubule-bound arrestin-2 
      Numerous lines of evidence demonstrate that the conformations of free and 
receptor-bound arrestin are substantially different (101-103). The N- and C-domains of 
arrestin are connected by a 12-residue loop termed the “hinge region” (Figure 1-2b) 
(104). Interestingly, progressive deletions in the inter-domain hinge that severely impede 
receptor binding, actually enhance MT binding of all arrestins, suggesting that the 
conformation of MT-bound arrestin differs from that of the receptor-bound form.  
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Figure 1-5. Arrestins bind microtubules in cells. 
(A) The percentage of arrestin in the cytoskeletal pellet fraction was quantified and 
analyzed by one-way ANOVA with arrestin type as the main factor. The percentage of 
arrestin3 in the pellet fraction is significantly greater than that of the other arrestins (*** 
p<0.001). (B) HEK293 cells expressing Flag-tagged arrestin3 or COS7 cells expressing 
untagged WT or Tr arrestin2 were fixed and stained as described in the Methods. White 
arrowheads indicate places where arrestin colocalization with microtubule bundles is 
most pronounced. Abbreviations: V, wild type visual rod arrestin; VD7, rod arrestin 
hinge deletion mutant; A2, wild type arrestin2; A2D7, arrestin2 hinge deletion mutant; 
A2Tr, truncated arrestin2(1-382); A3, wild type arrestin3; C, wild type cone arrestin. 
(Adapted from (100))  
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Importantly, the MT association of arrestin hinge deletion mutants was similarly 
enhanced in cells. 
To investigate binding elements of arrestin important for microtubule binding, 
site-directed spin labeling (SDSL) electron paramagnetic resonance (EPR) spectroscopy 
was used. This method requires the elimination of reactive native cysteines from the 
protein, the introduction of a unique cysteine at the position of interest, and subsequent 
modification of the cysteine with a sulfhydryl-specific spin label to generate the side 
chain R1. Cysteine residues at 16 different positions spanning the entire molecule on the 
background of fully functional cysteine-less arrestin-2 were introduced.  These spin-
labeled proteins were examined by EPR to determine microtubule-induced changes in R1 
mobility. 
Changes in mobility were detected for several positions on the-strands of the 
concave sides of both arrestin-2 domains. Some of the most dramatic changes occurred at 
four positions in the flexible “finger loop” between -strands V and VI.  Interestingly, 
both the concave sides of the N- and C-domain and the “finger loop” were recently 
shown to play a key role in receptor binding  (Figure 1-6a) (105).  Other residues located 
on the concave surface showed little to know movement in the presence of microtubules.  
Overall, the positions with the strongest changes in the spin label mobility define an 
extensive microtubule “footprint” on the arrestin-2 molecule (100) localized on the same 
surface that was previously implicated in receptor binding (102, 105, 106)  (Figure 1-6b) 
Because the MT-binding site covers the concave surfaces of both domains and 
significantly overlaps with the receptor-binding site indicating that arrestin cannot 
interact with the receptor and microtubules simultaneously.  Conceivably, arrestin  
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Figure 1-6.  Arrestins bind microtubules with the same interface as the receptor. 
(A) Visual arrestin crystal structure highlighting functional elements important for 
receptor binding as follows:  the “phosphate sensing” polar core, yellow; other phosphate 
binding residues, red; C-tail, orange; bulky hydrophobic residues participating in the 
three element interaction between b-strand I, a-helix I, and C-tail, blue; b-strands and 
loops shown to participate in receptor binding, green. (B) Summary of the changes in 
spin label mobility induced by arrestin interaction with MTs. Large changes in mobility 
indicate residues important in microtubule binding. The magnitude of the detected 
changes are highlighted on the arrestin2 crystal structure as follows:  positions with large 
decreases in mobility, dark blue; small decreases, light blue; no change, gray.  (Adapted 
from (18) and (100))  
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association with MTs may serve three functions (which are not mutually exclusive): 1) to 
keep arrestins away from receptors, similar to its apparent role in rod photoreceptors 
(107); 2) to sequester arrestin binding partners to regulate their activation; 3) to mobilize 
signaling proteins to the cytoskeleton and direct their activity toward MT-associated 
substrates.   The full range of biological implications of the functional link between 
arrestins and the cytoskeleton is unknown. 
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CHAPTER II 
 
ARRESTIN MOBILIZES SIGNALING PROTEINS TO THE CYTOSKELETON 
AND REDIRECTS THEIR ACTIVITY  
 
Much of the work in this chapter was published in the Journal of Molecular Biology in 
February 2007 (100) 
The paper was a collaborative effort between the laboratories of Vsevolod V. Gurevich, 
Vladlen Z. Slepak, and Candice S. Klug. 
 
Introduction 
        As their name implies, arrestins were originally described as proteins that 
terminate G protein-mediated signaling by binding the activated phosphorylated forms of 
their cognate G protein-coupled receptors (GPCRs) (reviewed in (5, 103, 108)). Recent 
discoveries of their interactions with numerous other binding partners revealed the role of 
arrestins as multi-functional regulators of cell signaling (reviewed in (109, 110)). 
Arrestins redirect GPCR signaling to G protein-independent pathways and determine the 
intracellular localization of key regulatory proteins. In particular, arrestin retains ERK2 
and JNK3 in complex with the receptor in the cytoplasm and removes Mdm2 and JNK3 
from the nucleus (reviewed in (109, 111, 112)). 
Most non-receptor partners bind the arrestin-receptor complex, engaging arrestin 
elements that are not involved in receptor binding (109, 112). Recently, we identified 
microtubules (MTs) as an interaction partner of visual arrestin-1.  The MT-binding site 
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on arrestins significantly overlaps with the receptor-binding site, but the conformations of 
MT-bound and receptor-bound arrestin are different. We found that arrestins recruit 
ERK1/2 and ubiquitin ligase Mdm2 to microtubules, differentially affecting their activity. 
Arrestin-dependent mobilization of signaling molecules to the cytoskeleton is an earlier 
unappreciated link in the network of cellular regulatory pathways.  
 
Materials and Methods 
Arrestin binding to microtubules in cells 
HEK-293A cells were transfected with expression plasmids encoding untagged arrestins 
and/or HA-Mdm2 and/or HA-ubiquitin using Lipofectamine 2000. 48 hours post-
transfection cells were incubated with 5  M taxol for 1.5 hours at 37oC and washed with 
80 mM PIPES pH 6.8, 70 mM NaCl, 1 mM MgCl2 (PB). Cells were cross-linked by 
incubation in PB, 5 µM taxol, and 2 mM DSP (Pierce) for 30 min and quenched by 
50mM Tris pH 7.4 for 15 min at RT before lysis in PB supplemented with 0.2% NP-40 
and 1mM PMSF.  Lysates were centrifuged at 400xg for 5min to remove cell debris. The 
supernatant was loaded onto a 60% glycerol cushion made in PB and microtubules were 
pelleted by centrifugation for 20 min at 25 °C
 
at 90,000 rpm in a TLA 120.1 rotor in a 
Beckman TL100 ultracentrifuge. The pellet was dissolved in Laemmli’s sample buffer 
and aliquots of the lysate, supernatant, and pellet were analyzed by Western blot using 
arrestin (F4C1), α-tubulin, Mdm2, HA (Sigma), ERK1/2, PP-ERK, JNK3, PP-JNK3 (Cell 
Signaling) or PP2A (BD Biosciences) antibodies. The cross-linking step was omitted in 
experiments designed to measure protein ubiquitination. 
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Results 
Functional consequences of the arrestin-microtubule interaction.  
Receptor-bound arrestins function as adaptors mobilizing the components of the 
trafficking machinery (6, 7) and recruiting a variety of signaling proteins to agonist-
activated GPCRs (109, 112). Non-visual arrestins serve as scaffolds for the ASK1-
MKK4-JNK3 and Raf-MEK-ERK1/2 MAP kinase cascades and target active ERK1/2 
and JNK3 to specific subcellular locations (109, 113-115). Ubiquitin ligase Mdm2 
interacts with receptor-bound (116) and free (117, 118) arrestins and plays a role in 
receptor ubiquitination (116, 119). The MT-binding site mapped by two different 
methods covers a large portion of the concave surface of both arrestin domains and 
overlaps with the receptor-binding site (102, 105, 106). Thus, arrestin cannot interact 
with the receptor and microtubules simultaneously. Most importantly, in MT- and 
receptor-bound arrestin the docking sites for non-receptor partners may be equally 
accessible, enabling arrestin-dependent mobilization of signaling proteins to the 
cytoskeleton. To test this idea, we examined the localization of two known arrestin 
partners, ERK1/2 and Mdm2, in cells expressing different arrestins. 
We found that the proportion of endogenous ERK1/2 present in the cytoskeletal 
fraction is significantly increased in cells expressing visual arrestin (arrestin-1), arrestin-2 
or arrestin-3 (Figure 2-1a,c), indicating that these three subtypes bring ERK to the 
microtubules. Arrestin-dependent mobilization of ERK to the receptor results in ERK 
activation by upstream kinases, c-Raf-1 and MEK1 (114). We tested whether this is also 
the case for ERK mobilized to MTs. The amount of active PP-ERK detected in the MT 
pellet fraction was negligible. However, the level of PP-ERK in the soluble fraction was  
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Figure 2-1. Arrestin-mediated sequestration of ERK to microtubules. 
(A,D) HEK-293 cells transfected with the indicated arrestins or empty vector (-) were 
fractionated as described in the Methods and analyzed by Western blot. Representative 
blots from 5 experiments demonstrating the relative amount of each protein in the lysate, 
soluble (sup), and cytoskeletal (pellet) fractions are shown. PP-ERK1/2 in the lysate (B) 
and total ERK1/2 in the cytoskeletal fraction (C) was quantified. The data were analyzed 
by one-way ANOVA with arrestin type as the main factor. *p<0.05, **p<0.01, *** 
p<0.001, compared to control. The percentage of ERK1/2 in the cytoskeletal fraction of 
control cells was 1.24 + 0.41 % of the total ERK in the cell. Abbreviations: V, WT visual 
arrestin-1; A2, WT arrestin-2; A3, WT arrestin-3; C, WT arrestin-4; PP-ERK, 
phosphorylated active ERK.  
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significantly affected by arrestin expression (Figure 2-1a,b). Rod and non-visual arrestins 
dramatically reduced active ERK (by ~50%). Importantly, cone arrestin, which does not 
mobilize ERK to MTs, did not have this effect, suggesting that arrestin-dependent 
mobilization of ERK to MTs decreases the total level of active ERK in the cell by 
removing ERK from cellular compartments where it can be activated. Indeed we found 
that arrestins do not increase the proportion of upstream kinases MEK1 and c-Raf-1 in 
the cytoskeletal fraction (Figure 2-1d), suggesting that the sequestration of an individual 
member of the MAP kinase cascade to MTs dampens signaling. 
The amount of endogenous Mdm2 present in the cytoskeletal fraction is also 
significantly increased in cells expressing rod and non-visual arrestins, but not cone 
arrestin (Figure 2-2a,b). Overexpressed HA-Mdm2 follows the same pattern (Figure 2-
2b). Because Mdm2 is an E3 ubiquitin ligase, we tested whether its arrestin-dependent 
mobilization to microtubules affects the ubiquitination status of associated proteins. As 
shown in Figure 2-2, rod arrestin dramatically increases the ubiquitination of numerous 
proteins in the cytoskeletal fraction. Rod arrestin also increases the overall level of 
protein ubiquitination, whereas arrestin-3 and cone arrestin reduce the total ubiquitination 
of most substrates, as compared to control cells (Figure 2-2a, total=sup+pellet; Figure 2-
2c, left panel). Interestingly, even though arrestin-3 significantly reduces total 
ubiquitination (more than any other arrestin), the percentage of the ubiquitinated proteins 
in the MT fraction of arrestin-3-expressing cells is elevated to the same extent as in cells 
expressing rod arrestin (Figure 2-2a, pellet; Figure 2-2c, right panel). Thus, the four 
arrestin subtypes differentially affect the mobilization of Mdm2 to microtubules and the 
ubiquitination of soluble and cytoskeletal proteins. 
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Figure 2-2. Arrestin recruits Mdm2 to microtubules. 
(A) HEK-293 cells transfected with the indicated arrestins or empty vector (-) were 
fractionated and analyzed by Western blot. A strong GADPH signal was detected in the 
supernatant, with no appreciable signal in the pellet. To measure ubiquitination of soluble 
and cytoskeletal substrates, cells were co-transfected with HA-tagged ubiquitin and 
ubiquitinated proteins were visualized with anti-HA antibody. Representative blots from 
3 experiments demonstrating the relative amount of each protein in the lysate, soluble 
(sup), and cytoskeletal (pellet) fractions are shown. Total ubiquitination was determined 
to be the amount of ubiquitinated substrate in the sup + pellet samples combined. (B) 
Endogenous Mdm2 in the cytoskeletal fraction in cells expressing different arrestins 
(black bars) (as shown in (A)) or endogenous plus overexpressed HA-Mdm2 (gray bars) 
was quantified and analyzed by one-way ANOVA with arrestin type as the main factor. 
*p<0.05, as compared to control. The amount of Mdm2 in the cytoskeletal fraction of 
control cells was 5.2 + 0.7 % and 8.7 + 0.8 % of the total Mdm2 for cells that did or did 
not express HA-Mdm2, respectively. (C) The total amount of ubiquitination (sup+pellet) 
(left graph) and percentage of protein-incorporated ubiquitin in the cytoskeletal fraction 
(pellet/(sup+pellet)) (right graph) was quantified by Western blot and analyzed by one-
way ANOVA with arrestin type as the main factor. *p<0.05, **p<0.01, compared to 
control. Abbreviations: V, WT visual rod arrestin; A2, WT arrestin2; A3, WT arrestin3; 
C, WT cone arrestin. 
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Additional experiments showed that arrestins recruit signaling proteins to MTs 
more selectively than to the receptor. In particular, we observed no arrestin-dependent 
mobilization of a different MAP kinase JNK3, phospho-JNK3  (113), or protein 
phosphatase 2A (120) (Figure 2-3). In summary, among the six binding partners tested, 
arrestins only bring two (ERK1/2 and Mdm2) to the microtubules. Apparently, the 
distinct conformation of MT-bound arrestin can only interact with a subset of proteins 
that have been shown to bind the arrestin-receptor complex.   
 
Discussion 
       The localization of the interaction sites for the non-receptor partners on the other 
side of the molecule allows arrestin to mobilize various signaling proteins to the receptor 
(109, 112). Our data show that microtubules bind to the same arrestin surface as the 
receptor (121), suggesting that the elements involved in the interactions with the non-
receptor partners should be accessible in the MT-bound form. Indeed, our finding that 
arrestin mobilizes ERK1/2 to the cytoskeleton clearly shows that this is the case (Figure 
2-1a,c). However, the functional capabilities of MT- and receptor-bound arrestin are 
different: arrestin mobilizes ERK, Mdm2, but not c-Raf-1, MEK1, or JNK3, whereas all 
of these partners are recruited to the arrestin-receptor complex.   
       Receptor binding induces a global conformational change in arrestin (103) that is 
widely believed to facilitate the binding of clathrin, AP2, Src, MAP kinases, and other 
proteins to the complex (109, 112). Deletions in the inter-domain hinge impede arrestin 
transition into this active conformation, thereby dramatically reducing arrestin binding to  
the receptor (104). In contrast, hinge deletions actually enhance arrestin binding to MTs,  
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Figure 2-3. Arrestins do not affect the subcellular distribution of JNK3 and PP2A. 
HEK-293 cells transfected with the indicated arrestins or empty vector (-) were 
fractionated as described in the Methods and analyzed by Western blot. Representative 
blots from 2-3 experiments demonstrating the relative amount of JNK3, phosphorylated 
JNK3 (PP-JNK3), and protein phosphatase 2A (PP2A) in the soluble (sup), and 
cytoskeletal (pellet) fractions are shown. For JNK3 experiments, cells were irradiated 
with UV for 30min at RT prior to crosslinking to increase the overall level of PP-JNK3. 
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suggesting that the conformations of MT-bound and receptor-bound arrestins are 
different. Not surprisingly, the functional consequences of arrestin-dependent ERK 
mobilization to the MTs is opposite to its recruitment to GPCRs. Receptor-bound arrestin 
facilitates ERK activation (114), whereas cytoskeletal localization of ERK by arrestin 
keeps it inactive, likely because arrestins do not mobilize the upstream kinases c-Raf-1 
and MEK1 to microtubules (Figure 2-4).      
 The binding of arrestin proteins to microtubules with affinities that ensure their 
partial co-localization with the cytoskeleton in intact cells is a novel link in the network 
of cellular signaling pathways. Accumulating evidence shows that a number of signaling 
proteins that were believed to selectively interact with receptor-bound arrestin actually 
bind free arrestin in the cytoplasm (117, 122, 123) and the microtubule-bound form. 
Notably, two out of the six arrestin partners tested in our study are recruited to 
microtubules in arrestin-dependent fashion. It is tempting to speculate that a number of 
other known binding partners may also be mobilized to the cytoskeleton via an arrestin-
dependent mechanism with significant functional consequences. The recruitment of 
signaling molecules may affect their activation state and/or microtubule dynamics, which 
is known to be regulated by post-translational modifications of tubulin and associated 
proteins (124). The full range of biological implications of the functional link between 
arrestins and the cytoskeleton remains to be elucidated. 
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Figure 2-4. Arrestin differentially recruits signaling proteins to the receptor and 
microtubules.   Arrestins recruit ERK opposite to its recruitment to GPCRs. Receptor-
bound arrestin facilitates ERK activation by also recruiting its upstream kinases Raf1 and 
MEK1. However, localization of ERK to the microtubules keeps in its inactive form, 
most likely because arrestins do not recruit its upstream kinases. As a result, arrestin 
dependent ERK1/2 mobilization to microtubules reduces ERK1/2 phophorylation level in 
the cell. The difference in recruitment is most likely the result of the different 
conformations of receptor-bound and microtubule-bound arrestin. 
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CHAPTER III 
 
ARRESTINS REGULATE CELL SPREADING AND MOTILITY VIA FOCAL 
ADHESION DYNAMICS 
 
Introduction 
Arrestins regulate G protein-coupled receptor (GPCR) signaling (1) and bind 
>100 non-receptor partners (125). The interactions of many proteins with GPCR-bound 
arrestin localizes them to receptor-rich membranes (126).  Recent studies implicated non-
visual arrestins in regulation of actin cytoskeleton and cell migration (50-53), but how 
arrestins contribute to these processes is unclear. Arrestin-2 activates small GTPase 
RhoA coordinately with Gαq following the activation of angitotensin II 1A receptor 
(ATII1AR) (70). Arrestin-2 also regulates RhoA activity by binding and inhibiting 
ARHGAP21, a RhoA GTPase activating protein, in response to ATII1AR stimulation 
(74). Arrestin-3 interacts with actin treadmilling protein cofilin upon activation of another 
GPCR, PAR2 (78). Both arrestin-2 and -3 regulate small GTPase ralGDS upon activation 
of fMLP receptor (75), and ELMO-ARF cascade upon calcium-sensing receptor 
stimulation (81).  All these studies suggest that arrestins regulate the cytoskeleton upon 
stimulation of specific GPCRs. Our finding that arrestins bind microtubules and recruit 
signaling proteins to them (100) suggests that arrestins may regulate the cytoskeleton 
independently of GPCRs. While this interaction has been characterized structurally (100, 
127), its functional significance was not fully elucidated. Therefore, we investigated the 
role of arrestins in cell migration and regulation of cell shape. 
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   Here we show for the first time that both arrestin-2 and arrestin-3 regulate 
signaling machinery involved in cell migration and spreading on two different levels. 
Arrestins affect the activity of small GTPases RhoA and Rac1, and also regulate focal 
adhesion dynamics independently of GPCRs and small GTPases.   
 
Material and Methods 
Antibodies 
 Rhodamine-phalloidin (for actin staining) was from Invitrogen (Invitrogen Carlsbad, 
CA); anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH), anti-HA, phospho-
paxillin (Y118), and monoclonal anti-Cdc42 antibodies were from Cell Signaling 
(Beverly, MA); anti-GFP monoclonal antibody, active 9EG7 and total Hmβ1-1 CD29 β1-
integrin, and monoclonal paxillin were from BD Biosciences (Palo Alto, CA);  rat IgGa,κ 
and hamster IgG isotype controls were from Biolegend (San Diego, CA). Monoclonal rat 
anti-HA antibody for cell staining was from Roche Molecular Biochemicals 
(Indianapolis, IN);  antibodies against mouse FAK, phospho-FAK (Y397), vinculin, and 
rabbit polyclonal α-tubulin were from Abcam (Cambridge, MA). Anti-Rac1 and Anti-
RhoA antibodies were from Millipore (Temecula, CA).  Mouse monoclonal pan-arrestin 
F4C1 antibody recognizing epitope DGVVLVD (residues 43-47) in the N-domain  was a 
generous gift of Dr. L.A. Donoso (Wills Eye Institute). Arrestins were detected with 
arrestin-2- (128) (1:6000) or arrestin-3-specific (129) (1:700) affinity-purified rabbit 
polyclonal antibodies. Total integrin antibody M-106 for Western blot and focal adhesion 
kinase (FAK) antibody for pull-down assay was from Santa Cruz Biotechnology (Santa 
Cruz, CA).  
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Cell culture, transfection, and retroviral infection of cells 
Arrestin DKO and WT MEF cell lines (21) (a gift from Dr. R.J. Lefkowitz, Duke 
University) were cultured in DMEM with 10% FBS and 1% penicillin-streptomycin (P/S) 
at 37 °C and 5% CO2.  Cells were retrovirally infected using genes inserted into pFB 
murine retrovirus vector (Stratagene) transfected using Lipofectamine 2000 (Sigma, St. 
Louis, MO) into Phoenix cell line.  Fugene HD (Promega, Fitchburg, WI) (1:3 
DNA:lipid) was used to transfect cells in some cases.  
 
Protein Preparation and Western-blotting 
Cells were lysed in Lysis solution (Ambion) or 1% SDS lysis buffer and boiled for 5 min 
at 95°C. Protein concentration was measured with Bradford reagent (Bio-Rad). The 
protein was precipitated with nine volumes of methanol, pelleted by centrifugation 
(10,000xg, 10 min at RT), washed with 90% methanol, dried and dissolved in SDS 
sample buffer at 0.5 mg/ml. Equal amounts of protein were analyzed by reducing SDS-
PAGE and Western blotting onto Immobilon-P (Millipore, Bedford, MA). The membrane 
was blocked with 5% non-fat dry milk in TBS with 0.1% Triton X-100 (TBST) and 
incubated with appropriate primary and then secondary antibodies coupled with 
horseradish peroxidase (Jackson Immunoresearch Laboratories, West Grove, PA) in 
TBST with 1% BSA. Bands were visualized with SuperSignal enhanced 
chemiluminescence reagent (Pierce, Rockford, IL) and detected by exposure to X-ray 
film (Fujifilm). Where appropriate, the bands were quantified using VersaDoc and 
QuantityOne software (BioRad). 
 
43 
 
Cell spreading and focal adhesion analysis 
All staining experiments were done as follows unless otherwise noted. Serum-starved 
cells were plated on 8-well slides coated with 1.25 ug/mL fibronectin or 0.1 mg/mL poly-
D-lysine. Cells were fixed with 4% paraformaldehyde, permeabilized with 0.4% Triton 
X-100, and blocked with 2% BSA in PBS. Most cells were stained with rhodamine-
phalloidin. Rescue experiments where DKO cells were infected to express HA-RhoA, 
HA-Rac mutants or HA-tagged arrestins were also stained with anti-HA antibody to 
detect expression. Most images were taken on Nikon wide field microscope. Focal 
adhesion numbers and size were quantified from confocal images taken on LSM 510 
Meta Confocal with 40X oil objective and analyzed with Image J. 
 
Migration Assay 
Cell migration analysis was performed as described in Transwell tissue culture inserts 
containing membranes with 0.8 M pores that were coated with 0.32 ug/mL fibronectin 
in PBS on the underside and kept overnight at 4
o
C.  Membranes were blocked in 1.5% 
bovine serum albumin (BSA) for 1 h at 37
o
C.  The 24-well inserts were placed in serum 
free medium and 10
6
 cells were seeded on the upper surface of the chamber and allowed 
to migrate for 4 h at 37
o
C. Cells that migrated were stained with 1% crystal violet and 6 
randomly chosen fields were counted at 200x magnification.  Migration rescue 
experiments were performed using cells infected with bicistronic vector co-expressing 
arrestin and GFP, or GFP alone. Cells were sorted for GFP expression on a BD 
FACSAria III cell sorter. 
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Adhesion Assay 
Adhesion assays were performed as described (130). 96-well plates were coated with 
increasing concentrations of fibronectin, 0.01 µg/mL to 1.25 µg/mL, and blocked with 
5% milk in PBS at room temp for 2 hrs. Serum-starved cells (6x10
5
) were plated and 
allowed to adhere for 15 or 30 min.  Unattached cells were removed using Percoll 
flotation medium (73mL Percoll (Sigma, density, 1.13g/mL), 27mL of distilled water, 
and 900mg NaCl) and the remaining cells were fixed for 15 min with 25% gluteraldehyde 
(Sigma), washed with PBS, and stained with 0.5% crystal violet (Sigma) in 20% 
methanol for 10 min.  Plates were washed with PBS and eluted with 20% acetic acid. 
Absorbance was read at 595nm.  Bars represent mean absorbance ± SEM of each 
condition
 
tested in triplicate. 
 
Replating Assay 
Replating assays were performed by trypsinizing cells, incubating them in suspension in 
serum-free DMEM and then plating serum-starved DKO and WT cells on 1.25µg/mL 
fibronectin for 0, 30, 60, and 120 min. Cells were lysed with 1% SDS lysis buffer. Levels 
of phosphorylated and total paxillin and FAK, and total vinculin were determined in cell 
lysates (5 μg/lane) by Western blot. 
 
Flow Cytometry 
To measure activity and surface expression of β1-integrin levels, cells incubated in Hanks 
balance salt solution (HBSS) (Cellgro, Manassas, VA) overnight were washed with Tris-
buffered saline (TBS) (24 mM Tris-HCl, pH 7.4, 137 mM NaCl, 2.7 mM KCl) and 
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resuspended in 5% bovine serum albumin (BSA).  Cells were incubated with 5mM 
MnCl2 or 2mM EDTA for 30 min at 37
o
C, then for 1 h with rat 9EG7 (active integrin) or 
hamster HMβ1-1 (total integrin) antibodies, or rat and hamster isotype controls. Cells 
were washed three times with 1% BSA in TBS and incubated for 45 min on ice with 
either Alexa Fluor 488 rabbit anti-rat (Invitrogen, Carlsbad, CA) or DyLight 488 
conjugated goat anti-hamster (Jackson Immunoresearch Laboratories, West Grove, PA) 
secondary antibodies.  At least 10,000 cells were analyzed using a 3 Laser LSRII 
machine to obtain mean fluorescence intensity values. To investigate total β1-integrin 
levels, equal numbers of DKO or WT cells were cultured for 2 days. Cell lysates were 
prepared in SDS lysis buffer after washing with PBS. Equal amounts of proteins were 
analysed by Western on 10% SDS-PAGE. 
 
GTPase Pulldown Assays 
The levels of GTP-liganded Rho were analyzed using the Rho activation pulldown kit 
according to manufacturer’s instructions (Millipore, Temecula, CA). Equal volumes of 
cell lysates were used to measure total Rho. PAK1-PBD-conjugated glutathione-
Sepharose beads were prepared as described (131). Cells were serum-starved for 24 hrs 
and lysed. Equal volumes of lysates were added to 30 μl of PAK1-PBD–conjugated 
glutathione-Sepharose beads and incubated at 4°C for 1 h with gentle rocking. After four 
washes with 125 mM HEPES, pH 7.5, 750 mM NaCl, 5% Igepal CA-630, 50 mM 
MgCl2, 5 mM EDTA and 10% glycerol, the beads were resuspended in 15 μl of 2× 
Laemmli SDS sample buffer, boiled for 5 min, and resolved on 15% SDS-PAGE. Equal 
volumes of total lysates were run for comparison. The proteins were transferred to a 
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nitrocellulose membrane and incubated with anti-Rac1 or anti-Cdc42 antibodies in 2% 
BSA at 4°C overnight.  
 
RhoA Inhibition 
WT cells were infected with retrovirus to express either dominant-negative RhoN19-HA 
or GFP and plated on fibronectin or poly-D for 2 hrs.  Cell size was measured in all 
conditions, focal adhesions were analyzed on fibronectin only. Cells were stained with 
Rhodamine-phalloidin and anti-HA or paxillin and anti-HA.  Alternatively, cells were 
allowed to spread for 2 h, and then incubated with 0.5µg/mL C3 Transferase 
(Cytokeleton, Denver, CO), a permeable Rho inhibitor, or with 1µM Y-27632, a selective 
inhibitor for Rho-associated kinases (ROCK) (EMD Chemicals, Inc., Darmstadt, 
Germany) for 4 hrs.  Cells were fixed and stained with rhodamine-phalloidin and anti-
paxillin antibody. 
 
Live Cell Imaging 
Imaging was performed using an Applied Precision DeltaVision Core microscope with a 
Plan Apo 60X oil immersion objective lens. DKO and WT cells expressing GFP-paxillin 
were placed in a heated microscope chamber at 37°C for 2 h prior to imaging. Images 
were then obtained every min and processed with 10 iterations of constrained iterative 
deconvolution using Softworx 5.0 (Applied Precision, Issaquah, WA).  Images were 
binned 2x2. Rescue experiments were performed with cells expressing either arrestin-2-
HA or arrestin-3-HA, mcherry-arrestin, and GFP. 
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Co-IP 
Rat-1 cells (60 mm plates) were lysed in 0.75 ml lysis buffer (10mM Tris-HCl(pH7.4), 
5mM EDTA, 150mM NaCl, 1% TritonX-100, 10% Glycerol, 1mM PMSF and 1mM 
NA3VO4) for 30-60 min at 4
o
C. After centrifugation, supernatants were pre-cleared by 35 
l of protein G agarose. Supernatants (500 g of total protein) were incubated with 2ul of 
Arrestin2 antibody (178) for 4 h, then with 20 l of protein G agarose beads (50% slurry) 
for 2 h. The beads were washed three times with 1 ml of lysis buffer, and the proteins 
were eluted with 50 l SDS sample buffer, boiled for 5 min, and analyzed by Western 
blot. 
 
Nocodazole Washout 
Serum-starved DKO and WT MEFs were grown overnight and treated with 10 µM 
nocodazole for 2 h to depolymerize microtubules. The drug was washed out 10x with 
serum-free medium and microtubules were allowed to repolymerize for 30, 60, 120 min.  
To stain for microtubules, cells were fixed with 1% gluteraldehyde in 1xBRB80  
followed by permeabilization with 0.5% TritonX-100 in 1xBRB80, or fixed with 4% 
PFA in PBS followed by treatment with 0.4% TritonX-100 in PBS before processing for 
immunofluorescence. Cells were stained with paxillin or α-tubulin antibodies.  Focal 
adhesion numbers were quantified in confocal images acquired with 40x oil objective 
using Image J. 
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Image and Statistical Analysis 
Most data were analyzed by one-way ANOVA with genotype as the main factor and 
subject to Bonferroni /Dunn post hoc test with correction for multiple comparisons unless 
noted otherwise.  Cell size analysis was from 10-15 randomly selected fields per 
experiment, and measured for area using Image J.  Cells with moderate expression of 
either HA-arrestins or HA-small GTPases were selected for cell size and focal adhesion 
number rescue measurements.  Focal adhesion size and number were measured from 
confocal images using Image J with qualifications for focal adhesion area: 0.5-100µm
2
.  
Focal adhesion lifetimes were calculated using focal adhesions containing GFP-paxillin 
that assembled and disassembled from the leading edge of the cell.  Focal adhesion size 
and lifetime distributions were measured using nonparametric analysis Kolmogorov 
Smirnov.  In all experiments a p value <0.05 is considered significant.  
 
Results 
Arrestins regulate cell morphology by altering the cytoskeleton.  
Arrestin-2/3 double knock-out (DKO) mouse embryonic fibroblasts (MEFs) were 
introduced more than a decade ago (21), but their peculiar shape, dramatically different 
from that of wild type (WT) MEFs, was routinely ignored. The actin cytoskeleton 
(visualized by Rhodamine-phalloidin staining) of arrestin DKO cells plated on 
fibronectin (FN) is drastically different from arresin-2 single knock-out (A2KO), arrestin-
3 single knock-out (A3KO) and WT cells (Figure 3-1a).  In addition, DKO cells are twice 
as large as A3KO and WT cells (Figure 3-1b), with the size of A2KO cells intermediate 
between cell types. To determine whether the increase in cell spreading of DKO cells was  
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Figure 3-1.  Knock-out of both arrestins results in dramatically altered cytoskeleton. 
(A) A2KO, A3KO, DKO and WT cells were stained with Rhodamine Phalloidin after 
spreading 2 h on FN or PDL. Scale bar = 10µm.  (B) The size of 50 cells in three 
experiments was quantified at each time point on either FN or poly-D-lysine ***p<0.001 
compared to WT, ###<p0.001 compared to A2KO.  (C) Expression of arrestins in A2KO, 
A3KO, DKO and WT cells were detected by western blot, with arrestin2 and arrestin3 
bovine standards for comparison.  Abbreviations:  A2KO, arrestin-2 single knock-out 
MEFs; A3KO, arrestin-3 single knock-out MEFs; DKO, Arrestin2/3 double knock-out 
MEFs; WT, wild-type MEFs; FN, fibronectin; PDL, Poly-D-lysine. 
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matrix dependent, we also plated cells on poly-D-lysine (PDL), which binds integrins but 
does not promote their clustering and activation. Interestingly, DKO cells spread as well 
on PDL as on FN (Figure 3-1a).  In contrast, all other cell types do not spread as well on 
PDL: the average cell area was reduced nearly by half from 1219 um
2
 on FN to 678 um
2 
(Figure 3-1b).    
To ascertain that the absence of arrestin-2/3 is responsible for the morphological 
phenotype of DKO cells, we tested whether expression of arrestin-2 or arrestin-3 rescues 
them, using cells expressing GFP as controls (Figure 3-2a). Cells plated on FN or PDL 
were stained for HA-tagged arrestins and actin cytoskeleton (Figure 3-2b). The 
expression of either non-visual arrestin (Figure 3-2e) reduces DKO cell size nearly back 
to WT on FN and PDL. Cells expressing arrestin-3 are closer to WT, whereas the rescue 
by arrestin-2 is partial Figure 3-2c,d). Thus, each non-visual arrestin significantly affects 
cell spreading. 
The best characterized function of arrestins is their high-affinity binding to active 
phosphorylated GPCRs (18). To test whether arresin interactions with GPCRs play a role 
in cell spreading, we used receptor binding-deficient arrestin mutants with 7-residue 
deletion in the inter-domain hinge (Δ7) (100, 132). Similar to WT arrestin-2 and -3, both 
Δ7 mutants effectively reduced the size of DKO cells to WT level on FN and PDL 
(Figure 3-2b,c,d,e). Thus, GPCR binding is not involved in arrestin-dependent regulation 
of cell spreading.   
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Figure 3-2.  Arrestin expression rescues DKO phenotype.  
DKO cells were retrovirally infected with HA-tagged arrestin-2, arrestin-2-Δ7, arrestin-3, 
arrestin-3-Δ7, or GFP as a control (DKO and WT). Cells were plated on FN and PDL. 
Arrestin expressing cells were stained for actin and HA (B) and control cells were stained 
for actin and GFP (A). Scale bar = 10µm. Arrestin expression is shown in (E). Cell size 
was measured on FN (C) and analyzed by one-way ANOVA with genotype as the main 
factor, ***p<0.001 DKO from all other conditions, DKO cells expressing arrestin-2 were 
statistically different from WT, ###p<0.01 according to Bonferroni /Dunn post hoc test 
with correction for multiple comparisons.  Data are from 37-82 cells per condition from 
3-4 experiments.  Cell size was also measured on PDL from 29-54 cells in 3 experiments 
(D) ***p=<0.001 DKO from all other conditions, DKO cells expressing arrestin2 were 
statistically different from WT, #p<0.05. 
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The activity of Rho family GTPases plays a role in DKO phenotype.  
Rho family GTPases (RhoA, Rac1, and Cdc42) regulate cytoskeleton via multiple 
effectors, controlling actin dynamics and cell shape (66).  Altered cytoskeleton and 
abnormal spreading of DKO cells are reminiscent of disregulated activity of small 
GTPases. Therefore, we measured the activity of RhoA, Rac1, and Cdc42 (133-135). The 
activity of RhoA and Rac1, but not Cdc42, was significantly decreased in DKO cells 
relative to WT (Figure 3-3a,b,c,d). MEFs where only arrestin-2 or arrestin-3 was missing 
had similarly decreased Rac1 activity (Figure 3-3f), suggesting that arrestin-2 and 
arrestin-3 regulate Rac1 via the same pathway. Conversely, cells lacking individual 
arrestins had near-normal RhoA activity (Figure 3-3e), suggesting that either arrestin can 
enhance RhoA activity and compensate for the loss of the other subtype. Indeed, 
overexpression of arrestin-2 or arrestin-3 in HEK293a cells dramatically increased RhoA 
activity (Figure 3-3g,h,i). Thus, both non-visual arrestins independently facilitate RhoA 
activation in different cell types. Therefore, the absence of both non-visual arrestins 
accounts for the decreased activity of RhoA and Rac1 in DKO cells. 
To test whether reduced RhoA and/or Rac1 activity fully explains DKO 
phenotype, in DKO cells we expressed HA-tagged constitutively-active and dominant-
negative RhoA and Rac1 mutants (136). The cells were stained for HA and actin (Figure 
3-4b) and measured the expression of GTPases (Figure 3-4e). DKO and WT cells 
expressing GFP alone served as controls (Figure 3-4a). The expression of constitutively 
active RacV12 did not reduce DKO cell size on FN, and even significantly increased it on 
PDL (Figure 3-4c,d,e).  Since Rac1 activation promotes cells spreading and membrane 
ruffling (68, 137), this is not surprising. Further suppression of Rho or Rac activity by  
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Figure 3-3.  Arrestins regulate the activity of RhoA and Rac1. 
(A) The levels of active RhoA, Rac1, and Cdc42 were detected by Western blot and 
active protein was quantified as a percent of total (B,C,D). Data were analyzed by one-
way ANOVA with cell type as the main factor **p<0.01, ***p<0.001 according to 
Bonferroni /Dunn post hoc test with correction for multiple comparisons.  Data taken 
from 3-4 experiments. (E,F) The levels of active RhoA and Rac1 in arrestin-2 and 
arrestin-3 single knock-outs were also were also compared to DKO and WT cells.  The 
data were analyzed by one-way ANOVA with cell type as the main factor.  *p<0.05 
compared to A3KO, ***p<0.001 compared to WT, #<0.05 compared to DKO according 
to Bonferroni /Dunn post hoc test with correction for multiple comparisons.  Data taken 
from 3 experiments.  (G) RhoA activity was measured using a GST-pulldown assay for 
active Rho in Hek293a cells overexpressing arrestin-2 or arrestin-3.  (H) Representative 
blot showing increase in activity. Expression levels of arrestin were measured by Western 
blot with pan-arrestin (F4C1) antibody (I).  Data from two different experiments were 
analyzed by one-way ANOVA, followed by post hoc Scheffe test with correction for 
multiple comparisons.  **p=0.045 arrestin-2 compared to control, **p=0.0046 arrestin-3 
compared to control.   
 
 
 
 
 
 
 
 
 
 
 
 
 
56 
 
 
 
 
57 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-4. Small GTPase RhoA affects cell spreading. 
(A) DKO and WT cells were retrovirally infected with GFP as control and DKO cells 
were infected with HA-RhoV14, HA-RhoN19, HA-RacV12, HA-RacN17 (B). (E) 
Expression of HA-tagged small GTPase mutants or GFP was determined by Western 
blot.   Cells were plated on FN or PDL. Scale bar = 10µM. Cell size was measured on FN 
(27-50 cells from 3 experiments) (C) and analyzed by one-way ANOVA, ***p<0.001. 
Cell size was also measured on PDL (26-40 cells from 3 experiments) (D) ***p<0.001 
from WT-GFP and DKO-RhoV14 cells. DKO cells expressing HA-RacV12 were 
significantly larger than control (GFP expressing) DKO cells, ##p<0.01. 
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dominant-negative RhoN19 or RacN17 did not change the morphology of DKO cells 
(Figure 3-4c,d,e). However, the expression of constitutively active RhoV14 significantly 
reduced DKO cell size to WT levels on both FN and PDL (Figure 3-4c,d). Thus, arrestin-
dependent RhoA, but not Rac1, activation contributes to the spreading phenotype of 
DKO cells.  
To further explore the effect of decreased RhoA on spreading we expressed 
dominant-negative RhoN19 in WT cells and plated them on FN or PDL (Figure 3-5a,b). 
As expected, WT cells expressing RhoN19 had fewer stress fibers than surrounding cells, 
but their size remained similar to GFP-expressing controls. Importantly, on PDL WT 
cells expressing RhoN19 spread significantly better than WT-GFP cells (Figure 3-5c). 
Similar effects were observed when RhoA signaling was suppressed in WT cells by a 
direct Rho inhibitor C3-transferase, or indirectly through ROCK inhibitor Y-27632. 
Under both conditions, treated WT cells spread significantly better than controls on PDL, 
but not FN (Figure 3-5d,e). Thus, constitutively active RhoA reduces DKO cell size to 
WT level, whereas suppression of RhoA activity in WT cells increases their size on PDL, 
suggesting that decreased RhoA activity significantly contributes to abnormal spreading 
of DKO MEFs. 
 
Arrestins regulate migration and adhesion. 
Cytoskeletal rearrangements drive cell movement and adhesion.  Therefore, we 
tested whether the lack of arrestins affects adhesion and migration. DKO cells 
demonstrated 3.8-fold reduced migration towards FN substrate in transwell assay (Figure 
3-6a). The adhesion of DKO cells was similar to WT after initial attachment (15 min)  
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Figure 3-5.  Reduced RhoA activity in WT cells increases cell spreading. 
(A)  WT cells were infected with dominant-negative HA-RhoN19 or GFP; the expression 
levels are shown in (B). Cells were plated on FN or PDL and stained for HA or 
Rhodamine-phalloidin.  Cell size measurements are shown in (C) ***p<0.001 compared 
to all other conditions, #p<0.05 WT-RhoN19 on poly-D compared to WT-RhoN19 on 
FN. Data from 55-69 cells in 4 experiments (means + SD) are shown.  (D) WT cells 
plated for two hours on FN or PDL and treated with C3-transferase (RhoA specific 
inhibitor), Y-27632 (ROCK inhibitor) or DMSO (control) for 4 hours. Cells were then 
stained with rhodamine-phalloidin and paxillin. The size was measured in 73-101 cells in 
3 experiments (E).  ***p<0.001 compared to control cells plated on PDL. Scale bar = 
10µM. 
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Figure 3-6.  Arrestins regulate cell migration and adhesion. 
(A) Cells were plated in Transwell chambers coated with 0.32 µg/mL FN and allowed to 
migrate for 4 h. Cells were counted in 6 fields/chamber in each of four independent 
experiments.  The data were analyzed by one-way ANOVA with cell type as the main 
factor, ***p= <0.001. Insets show representative membranes post migration. (B) 
Comparison of motility of single knock-out cell lines is also shown. The data were 
analyzed by one-way ANOVA with Genotype as the main factor.  ***p <0.001 compared 
to WT, ###p<0.001 compared to A3KO, @ p<0.05 compared to DKO. (C) 
Migration rescue experiments were performed with DKO cells expressing arrestin-2 and 
GFP or arrestin-3 and GFP, or cells expressing GFP only (DKO and WT). Data from 5 
fields/chamber from three independent experiments performed in duplicate were 
analyzed by one-way ANOVA with cell type as the main factor. ***p<0.001 compared to 
WT.  DKO-Arr2 ##p<0.01 and DKO-Arr3 #p<0.05 compared to DKO. Arrestin 
expression in DKO cells was determined using arrestin-2 or arrestin-3-specific 
antibodies, with corresponding purified bovine arrestins (0.1 ng/lane) run as standards 
(D).  Adhesion was measured by plating cells on serial dilutions of fibronectin 
(0.01µg/mL to 1.25µg/mL) for 15 (E) or 30 min (F). The data were analyzed by one-
way ANOVA with Arrestin type as the main factor, which was highly significant at 30 
min. DKO cells showed a dramatic increase in their ability to adhere, as compared to WT 
cells, ***p<0.001, **p<0.01.  Data was taken from 3 experiments for each time point. 
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(Figure 3-6e), but they adhered significantly better than WT as cells began to spread (30 
min) (Figure 3-6f). Thus, DKO cells form initial attachments similar to WT, but later 
demonstrate enhanced adhesion. 
To determine whether the reversal of DKO morphology by arrestin-2 or -3 also 
rescues motility deficit, DKO cells were infected with arrestin-2 or -3 in constructs that 
drive GFP co-expression, with controls expressing only GFP. Cells were sorted for GFP 
expression (Figure 3-6d) and used in transwell migration assay. Arrestin-2 and -3 
partially rescued the DKO migration defect (Figure 3-6c), suggesting that morphology 
and motility are regulated via the same arrestin-dependent mechanism(s), but both non-
visual arrestins likely work in concert to yield WT behavior. Arrestin-2 and arrestin-3 
single knockouts showed decreased migration, further proving this point (Figure 3-6b). 
 
Focal adhesion number and size are increased in arrestin-deficient cells.  
Focal adhesions (FAs) are key signaling hubs that recruit many proteins to the site 
of integrin activation (54, 138). Arrestins bind Src, ERK1/2, and JNK3 (18), all of which 
regulate FAs. Rapid assembly and disassembly of these complexes plays central role in 
cell adhesion and migration. Both decreased migration and increased adhesion of DKO 
cells suggest that FAs are likely affected. To test this idea, cells were stained with 
rhodamine-phalloidin and anti-paxillin antibody to visualize actin cytoskeleton and FAs, 
respectively. In WT MEFs we observed few FAs primarily at the edges of the cell on FN, 
and virtually none on PDL (Figure 3-7). Strikingly, in DKO cells the number of FAs was 
significantly increased. FAs in DKO MEFs demonstrate disordered localization 
throughout the cell on both FN and PDL (Figure 3-7a). The staining for two hallmarks of  
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Figure 3-7.  Arrestin knockout affects focal adhesion distribution. 
(A) Focal adhesions were detected in DKO and WT cells after 2 h on FN or PDL with 
anti-paxillin antibody. (B) The distribution of phospho-paxillin was visualized with 
antibody specific for paxillin phosphorylated at Y118.  (C) The distribution of focal 
adhesions stained with P-FAK (Y397) is similar to those visualized with P-paxillin 
(Y118) or total paxillin antibodies.  Scale bar = 10µm.    
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FAs, active phospho-paxillin (P-Y118) and phospho-FAK (P-Y397) (Figure 3-7b,c) 
revealed similar differences between WT and DKO cells. Importantly, in single knockout 
cells the FA pattern was similar to WT (Figure 3-8). These data suggest that arrestin-2 
and -3 participate in the regulation of FAs and cell size, and the magnitude of DKO 
phenotype reflects the absence of both arrestins. 
To quantify this difference we measured FA number as a function of time in WT 
and DKO MEFs (Figure 3-9a). After 2 hours on FN DKO cells have ~5-fold more FAs 
than WT. After 24 hours the number of FAs in DKO cells doubled, whereas WT cells 
showed only a slight increase (Figure 3-9b). The difference in FA size distribution 
between DKO and WT cells increased over time, with DKO cells demonstrating an 
accumulation of very large FAs at 24 hours (Figure 3-9c).   
 
Arrestins localize to focal adhesions and bind focal adhesion proteins 
To determine whether FA phenotype of DKO cells can be rescued by arrestins, 
we expressed HA-tagged WT and Δ7 arrestin-2 and -3 and stained for paxillin and HA to 
determine FA number in arrestin-expressing DKO cells (Figure 3-10b). DKO and WT 
cells expressing GFP were used as controls (Figure 3-10a), and only the cells expressing 
GFP or HA-tagged arrestins were used for analysis. We found that the expression of any 
of the four arrestin proteins reduces FA number, although not to WT level ((Figure 3-
10c).  Interestingly, we detected co-localization of arrestin-2-Δ7 with FAs (Figure 3-10b). 
We also found that FAK co-immunoprecipitates with arrestin-2 (Figure 3-10d), 
suggesting that arrestins bind this key component of FAs. These data suggest that  
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Figure 3-8. Arrestin single knock-out cells have focal adhesion intermediates 
between DKO and WT.  Focal adhesions were detected in A2KO, A3KO, DKO and 
WT cells after 2 h on FN or PDL with anti-paxillin antibody.  Scale bar = 10µm.   
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Figure 3-9.  Both focal adhesion number and size are increased in DKO cells. 
(A) Cells were plated on fibronectin for either 2 h or 24 h and focal adhesions were 
visualized by paxillin staining.  (B) The focal adhesions in DKO and WT cells plated on 
FN for 2 or 24 h were quantified and analyzed by two-way ANOVA with Genotype and 
Time as main factors. ***p<0.001 compared to WT, @@@p<0.001 DKO 24h compared 
to DKO 2 h, and ##p<0.01WT 24 h compared to WT 2h  according to Bonferroni /Dunn 
post hoc test with correction for multiple comparisons.  Measurements in 45-67 cells 
from 3 experiments were used. (C) Distribution of focal adhesion size is shown by 
scatter-plot. Focal adhesion size distributions were analyzed by nonparametric 
Kolmogorov Smirnov analysis, where DKO 2hr  p=0.0023, DKO 24h  p <0.0001, 24h 
p<0.0001 compared to WT 2h. Scale bar = 10µm. 
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Figure 3-10. Arrestins localize to focal adhesions and bind focal adhesion proteins. 
(A) Confocal images of DKO and WT cells expressing GFP or HA-tagged arrestins (B) 
and stained for paxillin.  Focal adhesion number was calculated in rescued arrestin-
expressing cells (C). Data were analyzed by one-way ANOVA with arrestin type as the 
main factor **p<0.01 DKO-arrestin-2, DKO-arrestin-3, DKO-arrestin-3-Δ7 compared to 
WT, ***p<0.001 DKO-arrestin-2-Δ7 compared to WT, ###p=<0.001 compared to DKO-
GFP according to Bonferroni /Dunn post hoc test with correction for multiple 
comparisons.  Scale bar = 10µM. (D) Co-IP of endogenous arrestin-2 with FAK.  
Arrestin-2 was pulled down with FAK-specific antibody, but not with control rabbit 
serum (NRS). 
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arrestins directly regulate FA dynamics via binding to one or more of FA-associated 
proteins.   
 
The absence of arrestins increases the activity of focal adhesion proteins. 
To compare signaling in FAs in WT and DKO MEFs, we measured the activity of 
focal adhesion kinase (FAK) and paxillin after plating the cells for different times on FN 
(Figure 3-11a). DKO cells showed increased activity of both proteins over WT at every 
time point, even at time zero before the cells contacted extracellular substrate (Figure 3-
11b,c). The total FAK was similar in WT and DKO cells (Figure 3-11e), while the total 
paxillin was even slightly lower in DKO (Figure 3-11d). Thus, higher percentage of 
paxillin and FAK was active in DKO cells than in WT. 
Integrins serve as the anchoring points that link the extracellular matrix to the 
signaling complexes that promote cytoskeleton rearrangement inside the cell. To 
determine whether the increase in activity of FA proteins was due to an increase in 
integrin activity, cells were stained with antibodies recognizing total and active β1-
integrin on the surface, and both were measured by FACs analysis (Figure 3-11f-h).  
Because integrins are activated by cations, staining for active β1-integrin was also 
performed in the presence of Mn
2+
 as a positive and EDTA as a negative control. We 
found no differences in active β1 integrin between DKO and WT cells (Figure 3-11h). 
However, we found that total (Figure 3-11f) and surface (Figure 3-11g) integrin in DKO 
cells was significantly higher than in WT.  Collectively, these results along with the 
adhesion data (Figure 3-6e,f) suggest that DKO cells form initial attachments similar to 
WT, but have an advantage in spreading due to increased availability of integrins. 
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Figure 3-11.  The activity of focal adhesion proteins is altered in DKO cells. 
(A)  Lysates from cells plated on FN for indicated times were blotted for focal adhesion 
proteins paxillin, P-paxillin, FAK, and P-FAK. Blots from three experiments were 
analyzed by one way-ANOVA with cell type as the main factor **p<0.01 *p<0.05 
(B,C,D,E) according to Bonferroni /Dunn post hoc test with correction for multiple 
comparisons.  Data is from three experiments. (F) Total levels of integrin were measured 
in DKO and WT lysates in 3 experiments and analyzed by one-way ANOVA **p<0.01.  
(G) Surface integrin levels were measured by FACs with control IgG isotype control 
subtracted from the mean fluorescence intensity, **p<0.01.  Data from 4 experiments 
(means + SD) are shown. (H) Active integrins were measured on cells treated with 2 mM 
EDTA, 5 mM Mn
2+
, or untreated controls.  ###p=<0.001 compared to EDTA treated 
cells, ***p<0.001 compared to untreated cells. Data from 3 experiments (means + SD) 
are shown. 
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The assembly and disassembly of FAs is affected by small GTPase signaling (67, 
68).  In particular, actin-myosin contractility mediated by ROCK activation via active 
RhoA provides tension within the cell that promotes the aggregation of integrins and an 
increase in associated FAs. If decreased RhoA activity in DKO cells is the main cause of 
increased FA number, the reduction of RhoA activity in WT cells should yield DKO-like 
phenotype. To test this idea, we expressed dominant-negative RhoN19 in WT cells and 
plated them on FN or PDL (Figure 3-12a). In contrast to DKO, FA number in cells 
expressing RhoN19 was lower than in WT controls (Figure 3-12b). Additionally, on PDL 
FAs were detected neither in WT-RhoN19 cells, nor control WT-GFP cells. Similar 
effects were observed when RhoA signaling was suppressed in WT cells by Rho inhibitor 
C3-transferase or ROCK inhibitor Y-27632. Under both conditions FAs were not 
decreased on FN and not detected on PDL (Figure 3-12b). Thus, increased number of 
FAs in DKO cells is not caused by reduced RhoA activity. 
 
Arrestins are necessary for rapid FA disassembly 
The accumulation and enlargement of FAs in DKO cells (Figure 3-9) along with 
increased activity of FA-associated proteins (Figure 3-11) suggests that the rate of FA 
disassembly might be reduced. To test this idea, we expressed GFP-paxillin in DKO and 
WT cells and measured FA lifetimes using live cell imaging (Figure 3-13a). Individual 
FAs at the leading edge of the cell were tracked from formation to disassembly 
(representative FAs are indicated by red arrows in Figure 3-13a). All FAs in WT cells 
formed and disassembled within 20-40 minutes (Figure 3-13b), with an average lifetime 
of ~25 minutes (Figure 3-13c). In contrast, lifetimes of FAs in DKO cells showed much  
74 
 
 
Figure 3-12.  RhoA does not play an arrestin-dependent role in focal adhesion 
regulation.  WT cells were infected with dominant-negative HA-RhoN19 or GFP.  (A) 
Cells were plated on FN or PDL and stained for actin plus HA or actin plus paxillin. (B) 
Focal adhesion number was measured in 25 cells in three independent experiments and 
analyzed by one-way ANOVA, ***p<0.001 compared to WT-GFP. 
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Figure 3-13. Arrestins regulate focal adhesion dynamics. 
(A)  DKO and WT cells expressing GFP-paxillin were viewed with DeltaVision Core 
microscope and images were captured at one-minute intervals.  Representative images at 
0, 10, 20, 30, 60, and 90  min are shown. Arrowheads indicate representative focal 
adhesions. Scale bar is 10 µM.  FA lifetimes were determined by counting the number of 
sequential frames where individual FA (GFP-paxillin) is visible. Histogram distributions 
of FA lifetimes are shown 20 min intervals (B). Data from 150 FAs in 15 cells for each 
cell type from 2-3 experiments. All distributions are significant from each other 
p<0.0001, except for DKO-Arr2 and DKO-Arr3 FA lifetimes, which are not significant 
according to nonparametric Kolmogorov Smirnov analysis. Insets show pre-images of 
cells used for still images, showing expression of GFP, indicative of arrestin expression, 
and mCherry-paxillin. (C) Mean FA lifetimes are shown. ***p<0.001 compared to WT, 
###p<0.001 compared to DKO. (D) Expression of arrestins and tagged paxillin 
determined by Western blot with bovine arrestin-2 and arrestin-3 (0.1ng/lane) as 
standards (Std).  
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broader distribution, with ~72 minutes average. Notably, some FAs in DKO cells 
persisted longer than 3 h (Figure 3-13a). DKO cells also demonstrated a defect in leading 
edge formation and loss of polarity. To test whether the defect in FA disassembly is a 
result of the lack of arrestins, we transfected red mCherry-paxillin in cells co-expressing 
GFP with arrestins (Figure 3-13d). Live cell imaging revealed a shift in FA lifetimes 
towards WT (Figure 3-13b), with an average of ~48 and 46 minutes in cells expressing 
arrestin-2 and arrestin-3, respectively (Figure 3-13c). Thus, arrestins regulate FA 
turnover, and normal dynamics require the presence of both subtypes. 
 
Microtubule targeting of focal adhesions is impaired in DKO cells 
Decreased RhoA signaling (139) and increased FAK activity (140, 141) promote 
FA disassembly. However, DKO cells have a dramatic defect in disassembly despite 
having both of these conditions. Thus, arrestins regulate FA turnover via additional 
mechanisms. Microtubule targeting of FAs promotes disassembly (142, 143). To test 
whether microtubule-dependent FA disassembly is altered in DKO cells, we treated cells 
with nocodazole to destabilize microtubules, and then monitored FAs as the microtubules 
re-grew (Figure 3-14a). Upon nocodazole treatment of WT cells the number of FAs 
doubled. In agreement with FA lifetimes determined in live cell imaging (Figure 3-
13b,c), after 30 min of nocodazole washout the number of FAs returned to baseline level, 
paralleling microtubule re-growth (Figure 3-14c). In contrast, DKO cells did not respond 
to microtubule destabilization, suggesting that microtubule loss has no effect on FAs in 
these cells (Figure 3-14b). Thus, arrestins likely participate in microtubule-dependent 
rapid FA disassembly. 
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Figure 3-14. Focal adhesion dynamics are altered in DKO cells with nocodazole 
treatment.  (A) DKO and WT cells were plated for 24 h, and were treated with or 
without 10 µM nocodazole for 2 h.  Nocodazole was washed-out and microtubules were 
allowed to re-grow for 30, 60 or 120 min. Paxillin or microtubules were visualized with 
respective antibodies. Focal adhesion number for each condition was calculated for DKO 
cells: (B) ***p<0.001, 30 min washout compared to untreated cells.  #p<0.05 compared 
to treated cells. **p<0.01 120 min washout compared to untreated cells.  WT cells: (C) 
***p<0.001 treated cells compared to all other conditions. Data were analyzed by one-
way ANOVA with treatment as the main factor, and subjected to Bonferroni /Dunn post 
hoc test with correction for multiple comparisons. Data taken from 40-50 cells per 
condition. Scale bar = 10µM. 
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Discussion 
Arrestins were first identified as terminators of GPCR signaling: arrestin binding 
to active phosphorylated receptors blocks G protein coupling (18). Subsequently, 
arrestins were shown to bind a variety of other proteins, including components of the 
endocytic machinery clathrin (144) and AP2 (145), MAP kinases (20, 41, 42, 44), 
ubiquitin ligases (146-148), and phosphodiesterase PDE4 (149). Arrestins have recently 
emerged as important players in cytoskeleton regulation via binding to microtubules 
(100), centrosome (150), and regulators of small GTPases (70, 72, 74). Despite clear 
interest in arrestin-dependent control of cytoskeleton (53, 151), very few mechanistic 
details have been established. Here we describe a dramatic phenotype of arrestin-2/3 
DKO MEFs, and demonstrate that arrestins regulate cell morphology by altering the 
cytoskeleton in a receptor-independent fashion. Cells lacking both arrestins have a 
dramatic increase in cell size in both matrix-dependent (FN) and matrix-independent 
(PDL) conditions.  
Small GTPases control cell shape by interacting with a variety of effectors that 
regulate the cytoskeleton. Dramatically altered morphology of DKO cells suggested that 
small GTPases are disregulated. Indeed, we found that basal activity of RhoA and Rac1 
were significantly reduced. The expression of constitutively-active RhoA mutant returned 
DKO cell size back to WT, whereas the reduction of RhoA activity in WT cells resulted 
in an increase of cell spreading on PDL, similar to DKO. RhoA was previously identified 
as an arrestin-2 target. RhoA-induced stress fiber formation was shown to be dependent 
on arrestin-2, but not arrestin-3, following activation of the ATII1AR receptor (70). 
Arrestin-2 was shown to bind RhoGTPase activating protein, ARHGAP21, a known 
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inhibitor of RhoA activity (74). In both studies arrestin knockdown reduced RhoA 
activity, similar to our observations in DKO cells (Figure 3-3). Although arrestins were 
previously shown to promote RhoA activation, our study yielded several novel insights. 
First, we showed that both arrestin-2 and arrestin-3 regulate RhoA activity independently 
of receptor activation. Knockout of either arrestin individually does not change RhoA 
activity, whereas overexpression of individual non-visual arrestins in HEK293a increased 
RhoA activity. Thus, both arrestin-2 and arrestin-3 facilitate RhoA activation. Second, 
here we show for the first time that arrestin-dependent regulation of RhoA activity 
directly affects cell spreading.   
Because the activity of signaling proteins that regulate the cytoskeleton is altered 
in DKO cells, we tested whether arrestins play a role in cell adhesion and migration. 
Arrestin-2/3 knockout decreased cell migration ~4-fold (Figure 3-6a), whereas the 
adhesion of DKO cells was enhanced (Figure 3-6f). Importantly, the rescue with 
individual arrestin-2 or arrestin-3 was partial, suggesting that both work together to 
control cell motility. A decrease in migration and an increase in adhesion suggest that 
FAs are altered in DKO cells. Indeed, we found that the numbers and sizes of FAs are 
dramatically increased in arrestin-null cells, and the difference with WT cells increases 
with time (Figure 3-9). Moreover, we found that arrrestin-2-Δ7 mutant co-localizes with 
FAs (Figure 3-10). In DKO cells we found higher levels of surface and total integrin, as 
well as increased activity of FAK and paxillin, even though total levels of these proteins 
were similar or even lower than in WT.   
 Rho-mediated myosin contractility promotes FA assembly by providing tension 
sufficient to cluster integrins (152). If higher RhoA activity increased the number of FAs, 
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one would expect increased RhoA activity in DKO cells, rather than the observed 
decrease (Figure 3-3b). We found that the reduction of RhoA activity by dominant-
negative mutant or specific Rho inhibitors in WT cells leads to a decrease, rather than an 
increase of FAs. These data suggest that arrestin knockout acts via a novel mechanism, 
apparent slowing FA disassembly (Figure 3-13). 
An increase in the activity of FA proteins and surface integrin both point to an 
impairment of FA turnover. Live cell imaging showed that FA lifetimes in DKO cells are 
dramatically longer than in WT. Importantly, the expression of arrestin-2 or -3 in DKO 
cells facilitates FA dynamics, although not to WT levels, suggesting that both are 
required for rapid FA turnover. A lot more is known about the assembly of FAs, than 
about their disassembly.  Several studies showed that a decrease in RhoA and an increase 
in FAK promotes FA disassembly (139-141).  However, DKO cells demonstrate 
impaired FA disassembly despite decreased RhoA and increased FAK activity, 
suggesting that arrestins regulate FA dynamics via other mechanisms.   
 Recently microtubule targeting has emerged as the predominant mediator of FA 
disassembly (142, 143).  One study (153) revealed that the Rho family GTPases are not 
involved and that FA disassembly requires microtubules and dynamin, neither of which 
participates in FA assembly. FAs in DKO cells do not respond to nocodazole treatment: 
additional FAs do not form when microtubules are destroyed, and FA disassembly is 
abnormal during microtubule re-growth in these cells (Figure 3-14). It is tempting to 
speculate that arrestins, known to bind microtubules (100), might serve as a link between 
microtubules and FA dynamics. Consistent with this idea, DKO and WT cells stained for 
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focal adhesion marker paxillin and microtubules shows that microtubules are improperly 
targeted to focal adhesions in DKO cells (Figure 3-15). 
The fact that dynamin is involved in microtubule-induced disassembly suggested 
that the rate-limiting step is endocytosis of integrins or other FA components (153). This 
was shown to be the case: integrin endocytosis mediated by clathrin and Dab2 is directly 
involved in microtubule-induced FA disassembly (153). It was suggested that 
microtubules deliver clathrin and Dab2 to FAs. Indeed, rapid accumulation of these 
proteins was documented when microtubules targeted FAs (154). Our data are compatible 
with this hypothesis. Higher proportion of β1-integrin on the surface of DKO cells is 
consistent with its impaired internalization. Arrestins participate in the endocytosis of 
GPCRs and other membrane receptors (27). Our finding that arrestin-2-Δ7 mutant with 
enhanced microtubule binding (100) shows subcellular localization similar to paxillin 
suggests that arrestins likely localize to FAs, which would place them in the proximity of 
integrins. The fact that this mutant, frozen in microtubule-bound conformation, shows 
stronger FA localization than WT (Figure 3-10b) suggests that binding to microtubules 
might facilitate arrestin localization to FAs. Upon GPCR binding arrestins undergo a 
distinct conformational change (27) that exposes binding sites for AP2 and clathrin (33) 
to initiate receptor endocytosis. Arrestins bind microtubules via the same interface as 
GPCRs (100), and AP2 and clathrin binding sites are exposed in the same manner (100). 
Thus, it is entirely possible that arrestins provide the link between microtubules and 
integrin endocytosis by recruiting clathrin to FAs, thereby promoting integrin 
internalization.    
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Figure 3-15.  Microtubules are not properly targeted to focal adhesions in DKO 
cells.  DKO and WT cells plated on fibronectin for 2 hours were stained with antibodies 
for α-tubulin and paxillin.   
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 Arrestins can facilitate FA disassembly via several mechanisms. Arrestin-2 and -3 
facilitate ERK1/2 activation (42, 155). Paxillin constitutively associates with MEK1 
(156) and is phosphorylated by ERK1/2 on several serine residues upon growth factor 
stimulation (157). Activation of hepatocyte growth factor receptor promotes recruitment 
of cRaf1 and ERK1/2, leading to the phosphorylation of paxillin by ERK1/2 (158, 159). 
Thus, arrestins may recruit ERK1/2 to the leading edge of the cell in proximity of 
paxillin. FA turnover may be affected in three ways by ERK1/2 activated via arrestins. 
First, phosphorylation of paxillin by ERK may destabilize FAK-paxillin interaction, 
leading to localized disassembly of focal contacts. Second, ERK phosphorylates and 
activates myosin light chain kinase (MLCK), another key factor shown to promote FA 
disassembly (140). Third, filamin, which regulates the trafficking of β1-integrins (160, 
161), binds arrestins and ERK1/2 (52). Interestingly, we recently found that 7 mutants 
of arrestin-2 and -3 bind ERK1/2 even better than parental WT proteins (162).   
 Our data reveal a completely novel function of arrestins. Arrestin-2 and arrestin-3 
individually regulate RhoA independently of GPCR stimulation to promote proper cell 
spreading. Arrestins also directly affect FA disassembly and migration, and this function 
requires both non-visual arrestins and is not mediated by small GTPases. Thus, non-
visual arrestins regulate cell spreading and migration via FA dynamics. Our results 
strongly suggest that non-visual arrestins might be the missing link between microtubules 
and FA disassembly. 
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CHAPTER IV 
 
PROGRESSIVE REDUCTION OF ITS EXPRESSION IN RODS REVEALS TWO 
POOLS OF ARRESTIN-1 IN THE OUTER SEGMENT WITH DIFFERENT 
ROLES IN PHOTORESPONSE RECOVERY 
 
This work was published in PLoS One in July 2011 (163). 
The paper was a collaborative effort between the laboratories of Vsevolod V. Gurevich, 
Jeannie Chen, and Eugenia V. Gurevich 
 
Introduction 
Humans express ~800 different G-protein-coupled receptor (GPCR), among 
which rhodopsin is the best characterized (164). Rod phototransduction is the only 
GPCR-driven signaling cascade where the expression levels of all players are known with 
sufficient precision to model systems behavior of the cell (165-168).  The biochemical 
mechanism of rod phototransduction serves as a model of GPCR-driven signaling 
cascade (164).  Light activates rhodopsin by converting covalently linked 11-cis-retinal to 
all-trans-retinal. Active rhodopsin catalyzes GDP/GTP exchange on a heterotrimeric G 
protein transducin, which in turn activates cGMP phosphodiesterase. The hydrolysis of 
cGMP rapidly reduces its concentration, leading to the closure of cGMP-gated cation 
channels, which suppresses circulating current. Single photon sensitivity (169) and fine 
temporal resolution of the rod is ensured by the shutoff of rhodopsin signaling with sub-
second kinetics (167, 170). Rhodopsin is turned off by a two-step mechanism. First, 
87 
 
GRK1 (also known as rhodopsin kinase) specifically binds activated rhodopsin and 
phosphorylates its C-terminus (171). When the number of rhodopsin-attached phosphates 
reaches three (85, 86), arrestin-1
a
 binds the receptor with high affinity, sterically 
precluding further transducin activation (88, 172). Mouse rods express arrestin-1 
and rhodopsin at ~0.8:1 ratio, making arrestin-1 the second most abundant protein in the 
rod photoreceptor (92, 173, 174).  Using transgenic mice expressing arrestin-1 at levels 
ranging from  4% to 220% of  WT, we recently found that supra-physiological arrestin-1 
levels marginally improve the functional performance of rods (174). Reduced arrestin-1 
levels are adequate at dim light, but impair functional performance at brighter 
illumination (174). Importantly, the reduction of arrestin-1 level in the OS to ~2.5% of 
WT dramatically slowed the recovery kinetics, as compared to mice with only twice as 
much arrestin-1 in the OS (174). Here we show that, while the recovery rates in all lines 
slow with the increased intensity of the desensitizing flash, the same “threshold” between 
5% and 2.5% of arrestin-1 level in the OS is observed. These data indicate that ~2.5% of 
arrestin-1 content in the OS is not immediately available for rhodopsin quenching, 
suggesting that this separate pool of arrestin-1 resides relatively far from rhodopsin-
containing discs. Slow diffusion of arrestin-1 across the OS in the lowest expressing line 
apparently delays the recovery by making rhodopsin inactivation rate-limiting, in contrast 
to WT and arrestin-1 hemizygous (Arr1+/-) animals where transducin inactivation is the 
slowest process that determines the speed of recovery (167, 170, 175).  
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Materials and Methods 
Ethics Statement 
Animal research was conducted in compliance with the NIH Guide for the Care and Use 
of Laboratory Animals and approved by the institutional Animal Care and Use 
Committee (protocol ID M/06/091). 
 
Generation of transgenic mice expressing arrestin-1 at different levels. 
Transgenic mice expressing different levels of arrestin-1 were described previously (92, 
97, 174), and the arrestin-1 content in the dark-adapted OS of these mice was determined 
(174).   
 
Electroretinography (ERG) 
Electroretinograms were recorded from 6 to 8 week old mice reared in 12/12 light-dark 
cycle (90+10 lux in the cage during light period) and dark-adapted overnight, as 
described (174, 176).  Briefly, under dim red light, mice were anesthetized by i.p. 
injection of (in µg/g body weight) 15-20 ketamine, 6-8 xylazine, 600-800 urethane in 
PBS. The pupils were dilated with 1% tropicamide in PBS. An eye electrode made with a 
coiled 0.2mm platinum wire was placed on the cornea, a tungsten needle reference 
electrode in the cheek, and ground needle electrode in the tail (177-179).  ERG was 
recorded with the universal testing and electrophysiologic system UTAS E-3000 (LKC 
Technologies, Inc.). A Ganzfeld chamber was used to produce brief (from 20µs to 1ms) 
full field flash stimuli. The light intensity was calibrated by the manufacturer and 
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computer controlled. The mouse was placed on a heating pad connected to a temperature 
control unit to maintain the temperature at 37-38
o
C throughout the experiment. 
Double-flash protocol.  The double flash recording was used to analyze the kinetics of 
recovery (177, 180). A test flash was delivered to suppress the circulating current of the 
rod photoreceptors. The recovery was monitored by delivering a second (probe) flash 
after time interval between the two flashes, which was varied from 200 to 120,000 ms. 
The intensity of the test flash was either -0.8, -0.4, 0, or +0.4 logcd*s/m
2
, corresponding 
to ~160, ~400, ~ 1000, and ~2500 photoisomerizations per rod (179).  The following 
probe flash was 0.65 logcd*s/m
2
, corresponding to ~4,500 isomerizations per rod (179).  
Sufficient time for dark adaptation was allowed between trials, as determined by the 
reproducibility of the response to the test flash. Time-to-peak (implicit time) of the a-
wave at the intensity of the probe flash was similar across different genotypes. This 
finding along with the shape of the a-wave indicates that the intrusion of b-wave and 
oscillation potentials (180, 181) did not differentially affect different genotypes. The 
normalized amplitude of the probe flash a-wave was plotted as a function of time 
between the two flashes. Instead of fitting the data points to a theoretical equation, which 
is inevitably based on certain assumptions that may not be correct for all of the genotypes 
used in this study, we fitted curves with polynomial nonlinear regression using GraphPad 
Prism (Version 4.0) and cosindered R
2
>0.95 as a criterion for a good fit.  The rate of 
recovery was characterized by the time interval necessary for half recovery  (thalf).  
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Statistical Analysis 
The data were analyzed by for each light level separately by one-way ANOVA with 
Genotype as main factor. To examine the change in recovery time with light intensity, the 
data for each genotype was analyzed separately with light as main factor. Means were 
compared using Bonferroni post hoc test with correction for multiple comparisons. In all 
cases, p<0.05 was considered significant.  
 
Results 
      Arrestin-1, acting after GRK1 phosphorylation of rhodopsin (182, 183), is the key 
player in rapid photoresponse recovery in rods (184) and cones (185). In the dark, 
arrestin1 translocates out of OS and localizes primarily to cell bodies of rod 
photoreceptors, so the OS contains only a small proportion of arrestin-1 (92, 95, 173, 
174, 186, 187). Dark-adapted rod OS of transgenic mice expressing arrestin-1 at 4% (Tr-
4
Arr-/-
), 12% (Tr-12
Arr-/-
), 50% (Arr+/-), and 100% of WT contain ~ 7.6, 15, 180, and 300 
M arrestin-1, respectively (these calculations are based on 3 mM rhodopsin 
concentration in the OS (82, 174)), which constitutes 2.5%, 5%, 60%, and 100% of 
normal WT level, respectively. Rod function can be monitored non-invasively by ERG, 
where the suppression of rod circulating current is reflected by a negative a-wave 
response (177, 180, 188, 189). We used double-flash protocol, where an initial flash 
desensitizes rods, and the response to the second (probe) flash, delivered at varying time 
intervals after the initial flash, is measured to determine the extent of recovery. The time 
of half-recovery (thalf) is calculated by plotting the amplitude of the probe flash response 
as a function of time between flashes (177). Using desensitizing flash of -0.4 logcd*s/m
2
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(400 photoisomerizations/rod), we previously found that recovery rates of the three lines 
with 100%, 60%, and 5% of WT arrestin-1 level in the OS are surprisingly similar, 
whereas rod recovery in mice with 2.5% of normal arrestin-1 content in the OS is 
dramatically slowed (Figure 4-1) (174). Considering that the pseudo-first-order rate of 
arrestin-1 binding to phosphorylated rhodopsin is the product of the on-rate constant 
(which was recently measured (190)) multiplied by the absolute arrestin-1 concentration 
near rhodopsin-containing discs, two mechanistic models could account for this 
“threshold”-like effect. If arrestin-1 is homogeneously distributed throughout OS 
cytoplasm, the threshold must depend on the intensity of the desensitizing flash, so that 
the activation of more than twice as many rhodopsins should place Tr-12
Arr-/-
 mice with 
two-fold greater arrestin-1 content below the threshold. Alternatively, arrestin-1 
distribution in the OS may be non-homogeneous, with immediately available and 
relatively unavailable pools. If the latter pool is roughly equal to arrestin-1 content in the 
lowest expressing animals, Tr-4
Arr-/-
 mice would be below the threshold at all intensities 
of desensitizing flash, whereas all other lines would remain above it. To distinguish 
between these two possibilities, we used initial desensitizing flashes with intensities that 
vary ~16-fold, -0.8, -0.4, 0, and +0.4 logcd*s/m
2
,
 
corresponding to 160, 400, 1000, and 
2500 photoisomerizations/rod (Figure 4-1,2; Table 4-1). Unexpectedly, we found no 
significant differences in the thalf of WT, Arr+/-, and Tr-12
Arr-/-
 mice at any intensity of 
desensitizing flash tested, despite ~20-fold difference in the arrestin-1 content in the OS 
of WT and Tr-12
Arr-/-
 animals. However, the magnitude of the recovery defect in Tr-4
Arr-/-
 
mice depended on flash intensity. At 160 photoisomerizations/rod, thalf of Tr-4
Arr-/-
 mice 
was only ~1.8-fold longer than in other genotypes, but the difference increased to ~5.5-,  
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Figure 4-1.  Reduced arrestin-1 expression slows down photoresponse recovery.   
The intensities of the first (desensitizing) flashes were -0.8, -0.4, 0, or +0.4 logcd*s/m
2 
and second (probe) flash was 0.65 logcd*s/m
2
. The a-wave elicited by the probe flash 
was plotted as a function of time elapsed after the first flash. Representative recovery 
curves for indicated genotypes and strengths of desensitizing flash are shown. The 
interval between the two flashes was varied from 200 to 120,000ms. Phi/rod, 
photoisomerizations/rod. 
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Figure 4-2. Animals with very low arrestin-1 in the OS show very long time of half 
recovery.  To calculate the time of half recovery, recovery kinetics were fitted by 
polynomial nonlinear regression, with R
2
>0.95, as described in methods. Means +/- SD 
for four animals per genotype are shown. The data were analyzed by one-way ANOVA 
with Genotype as main factor followed by Bonferroni post hoc comparison of means. * - 
p<0.05; ** - p<.001, *** - p<0.001 to WT; + - p<0.05, ++ - p<0.001, +++ - p<0.001 to 
Arr+/-, a – p<0.005, b – p<0.01, c – p<0.001 to Tr-12Arr-/-. Phi/rod, 
photoisomerizations/rod. 
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Genotype 158 
phi/rod 
398 phi/rod 1000 phi/rod 2512 phi/rod Arrestin-1 
concentration 
(OS) 
Wild type 258 + 45 
ms 
376 + 47 ms 405 + 58 ms 646 + 56 ms 300 µM 
Arr1
+/-
 262 + 35 
ms 
426 + 26 ms 486 + 82 ms 626 + 79 ms 180 µM 
Tr-12
Arr1-/-
 278 + 46 
ms 
433 + 45 ms 460 + 75 ms 718 + 27 ms 15 µM 
Tr-4
 Arr1-/-
 514 + 183 
ms 
2368 + 1515 
ms 
5515 + 999 
ms 
14137 + 3595 
ms 
7.6 µM 
 
 
Table 4-1. The rates of photoresponse recovery in mice with different arrestin-1 
expression. Initial desensitizing flashes with intensities that vary ~16-fold, -0.8, -0.4, 0, 
and +0.4 logcd*s/m
2
,
 
corresponding to 160, 400, 1000, and 2500 photoisomerizations/rod 
were used. The magnitude of the recovery defect in Tr-4
Arr-/-
 mice depended on flash 
intensity. At 160 photoisomerizations/rod, thalf of Tr-4
Arr-/-
 mice was only ~1.8-fold longer 
than in other genotypes, but the difference increased to ~5.5-, 12-, and 23-fold at 400, 
1000, and 2500 photoisomerizations/rod, respectively.  In WT, Arr+/-, and Tr-12
Arr-/-
 
mice, thalf increased ~2.5-fold with the desensitizing flash inducing 2,500 instead of 160 
photoisomerizations/rod.  In sharp contrast, the increase in recovery time from the 
dimmest to brightest desensitizing flash for Tr-4
Arr-/-
 mice was ~28 fold. 
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12-, and 23-fold at 400, 1000, and 2500 photoisomerizations/rod, respectively (Figure 4-
2; Table 4-1).  
Importantly, WT, Arr+/-, and Tr-12
Arr-/-
 mice demonstrated a gradual slowing of 
the recovery with increasing intensity of the desensitizing flash, and the slope of the 
slowing was the same in these three genotypes, as evidenced by lack of interaction 
between Genotype and Light factors in two-way-ANOVA (F(6,41)-1.12, p=0.37 n.s.). In 
these genotypes thalf increased ~2.5-fold with desensitizing flash inducing 2,500 instead 
of 160 photoisomerizations/rod (Table 4-1). In sharp contrast, the increase in recovery 
time from the dimmest to brightest desensitizing flash for Tr-4
Arr-/-
 mice was ~28 fold 
(Table 4-1). Virtually identical slowing of the recovery in WT, Arr+/-, and Tr-12
Arr-/-
 
animals likely reflects the increased time that it takes guanylyl cyclase to replenish 
hydrolyzed cGMP necessary to open cGMP-gated channels and restore circulating 
current, whereas much more dramatic increase of thalf in Tr-4
Arr-/-
 animals must reflect 
additional processes that do not operate in the other three genotypes.  
Discussion 
      Comprehensive understanding of systems behavior of rod photoreceptors requires 
precise knowledge of the concentration, localization, and activity of every signaling 
protein in the cell. While the functional role of many signaling proteins in rod 
phototransduction have been qualitatively established using genetically modified mice 
(reviewed in (83)), the biological significance of the specific level of each protein is 
rarely addressed. The studies where rods with different expression levels of rhodopsin 
(191, 192), RGS9 (170, 175), GRK1 (193), and arrestin (174, 175, 193) were functionally 
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characterized yielded seminal, often unanticipated, results. Here we report an unexpected 
finding that 20-fold reduction of arrestin-1 content in the dark-adapted rod OS from 
100% to 5% of WT level has no appreciable effect on photoresponse recovery, whereas 
further 2-fold reduction to 2.5% dramatically slows this process (Figure 4-1,2; Table 4-
1). This remarkable difference in recovery kinetics is unlikely to be simply the result of 
depletion of arrestin-1 in the OS. The calculated amount of arrestin-1 present in the OS 
for Tr-4
Arr-/-
 mice is approximately 7.6 µM, which corresponds to about 200,000 
molecules per OS (174). Mouse OS contains ~10
8
 rhodopsins in ~800 disks (82), or 
~125,000 rhodopsins per disc. In the case of even arrestin-1 distribution in the OS there 
would be ~250 arrestin-1 molecules per disc available to quench rhodopsin. However, 
even at the dimmest desensitizing flash used, which generates only 160 Rh*/rod (0.2 
Rh*/disc), we observed a 1.8-fold slowing of the recovery, which increases to >20-fold at 
3 Rh*/disc (Table 4-1). Arrestin-1 concentration in the WT mouse OS is ~300 µM (174). 
Taking into account known constants of mouse arrestin-1 self-association (194), this 
yields ~ 50 µM active monomer. This results in estimated pseudo-first-order on-rate of 50 
s
-1
, enabling arrestin-1 to “check” the state of each rhodopsin molecule every 20 msec. 
This is consistent with recent estimates of an active rhodopsin lifetime of <60 ms (170), 
or possibly even ~30 ms (167, 175). Average arrestin-1 concentration in the OS of Tr-
4
Arr-/-
 mice is ~ 7.6 µM (174), so that arrestin-1 would be able to encounter each 
rhodopsin every 200 ms. This difference is sufficient to account for ~200 ms delay, but 
cannot explain the multi-second times of half-recovery observed (Figure 4-2; Table 4-1). 
Thus, our data suggest that most of arrestin-1 in the OS of Tr-4
Arr-/-
 animals is not 
immediately available for rhodopsin quenching. 
97 
 
        Self-association could potentially limit arrestin-1 availability. Arrestin-1 forms 
dimers and tetramers at physiological concentrations (195-197), yet only the monomer is 
capable of binding rhodopsin (197, 198), because the well-defined rhodopsin-binding 
surface of each molecule (25, 106, 194, 199-204) is occluded by other subunits in the 
solution tetramer (198). Recent measurements of self-association constants of mouse 
arrestin-1 yielded Kd dimer = 57.5 µM and Kd tetramer = 63.1 µM (194). These values allow 
the calculation of the half-life of the dimer and tetramer (205), both of which turn out to 
be on the order of 12 ms. Thus, arrestin-1 self-association also cannot account for the 
multi-second times of half-recovery in Tr-4
Arr-/-
 mice (Table 4-1). 
          Sub-cellular distribution of arrestin-1 in rods is strictly light dependent. In the dark, 
arrestin-1 is predominantly located in the inner segment, perinuclear layer, and synaptic 
terminals, with relatively small fraction, estimated at 2-4% (92, 97), 9% (173), or ~15% 
(174), residing in the OS. Prolonged bright illumination triggers the translocation of the 
majority of arrestin-1 to the OS (97, 186, 206). Different lines of evidence suggest that 
arrestin-1 movement is either energy-independent, driven by diffusion (97), or may 
involve active transport (207), or possibly diffusion with active gating in the cilium 
(173). Considering that in the light and dark arrestin-1 in the rod is at disequilibrium 
(208), it is clear that, regardless of the mode of transportation, its distribution must be 
determined by the interactions with non-mobile partners: otherwise the diffusion would 
quickly ruin concentration gradients created by any mechanism (209). Arrestin-1 binds 
rhodopsin at 1:1 ratio (89, 90), and the molar amount of arrestin-1 that can translocate to 
the OS in the light is limited by the amount of rhodopsin present in this compartment 
(92), indicating that rhodopsin is the immobile binding partner that holds arrestin-1 in the 
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OS in the light. Arrestin-1 binds several proteins present in the cell body, including 
polymerized tubulin (microtubules) (210, 211), c-Jun N-terminal kinase (39), ubiquitin 
ligase Mdm2 (39), calmodulin (35), N-ethylmaleimide-sensitive factor (212), and 
enolase1 (213). Among these, however, tubulin appears to be the only sufficiently 
abundant protein to serve as an “anchor” for arrestin-1 expressed at 0.8:1 ratio to 
rhodopsin (92, 173, 174). High concentration of arrestin-1 in the compartments 
particularly rich in microtubules (the inner segment, perinuclear area, and synaptic 
terminals (214)) in the dark supports this notion. Arrestin-1 translocation is a relatively 
slow process that takes many minutes (97, 173, 206). Thus, in dark-adapted animals used 
in this study arrestin-1 already present in the OS must be responsible for signal shutoff.  
Microtubules are not abundant in the OS, but several bundles near the outer membrane 
extend along the full length of the OS and the axoneme (95, 214). The diameter of mouse 
rod OS is ~1.4 m (165), so that arrestin-1 bound to these microtubules would need to 
diffuse for up to 0.7 m before reaching rhodopsin. This would take seconds (165), 
which matches the observed delay of photoresponse recovery in Tr-4
Arr-/-
 mice, as 
compared to the Tr-12
Arr-/-
 animals (Table 4-1), fairly well. Thus, the simplest model that 
accounts for our data is that there are two distinct pools of arrestin-1 in the OS. At least 
2.5% is bound to the microtubules at the plasma membrane, whereas the rest is 
distributed throughout OS cytoplasm, with only the latter being available to quench 
rhodopsin signaling on the millisecond timescale. In Tr-4
Arr-/-
 animals microtubules take 
up most of the arrestin-1 present, leaving relatively little immediately available to 
rhodopsin. This slows down shutoff by the time necessary for arrestin-1 diffusion across 
the OS. In contrast, in Tr-12
Arr-/-
 mice and higher expressors the microtubules in the OS 
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apparently saturate by the amount of arrestin-1 roughly equal to that present in Tr-4
Arr-/-
 
animals, allowing the rest of arrestin-1 to freely distribute in the cytoplasm to be 
immediately available for rhodopsin shutoff (Figure 4-3).  
       In summary, our data suggest the existence of two distinct pools of arrestin-1 in dark-
adapted mouse outer segments. To the best of our knowledge, so far only one genetically 
modified mouse line where rhodopsin shutoff was made rate-limiting was described: 
mice with low expression of GRK1/2 chimera (215). In Tr-4
Arr-/-
 mice we made 
rhodopsin shutoff the rate-limiting stage of photoresponse recovery by low expression of 
arrestin-1. Collectively, these results strongly support the idea that both phosphorylation 
and arrestin binding are necessary steps in rhodopsin shutoff. 
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Figure 4-3. There are two distinct pools of arrestin in the OS in the dark: 
microtubule bound, and cytoplasmic. 
Because arrestin translocation happens on the order of minutes, arrestin already in the OS 
must be available to quench rhodopsin signaling with sub-second kinetics in dim light.  
The simplest model that accounts for our data is that there are two distinct pools of 
arrestin-1 in the OS in the dark.  (A) Rod photoreceptors have microtubules that extend 
along the axoneme of the OS.  (B) In WT animals, at least 2.5% is bound to the 
microtubules at the plasma membrane, whereas the rest is distributed throughout OS 
cytoplasm, with only the latter being available to quench rhodopsin signaling on the 
millisecond timescale. (C) In Tr-12
Arr-/-
 animals, the level of arrestin in the OS is reduced, 
however there is enough arrestin to saturate the microtubules, with protein left over to 
quench rhodopsin singling. (D) In Tr-4
Arr-/-
 animals, however, microtubules take up most 
of the arrestin-1 present, leaving relatively little immediately available to rhodopsin. This 
slows down shutoff by the time necessary for arrestin-1 diffusion across the OS.  
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CHAPTER V 
 
THE CONFORMATION OF RECEPTOR-BOUND ARRESTIN 
 
Introduction 
Arrestin was first discovered in the visual system as a protein that blocks the 
signaling of the prototypical G protein-coupled receptor (GPCR) rhodopsin (Rh) via 
specific binding to P-Rh* (216).  The discovery of non-visual arrestins (16) showed that 
phosphorylation followed by arrestin binding is the common mechanism of GPCR 
regulation.  Crystal structures of all four arrestin subtypes (30, 217-219) in their basal 
state revealed similar topology: the two cup-like domains linked by an inter-domain 
hinge (Fig. 1).  
Arrestin-1 shows a remarkable selectivity for P-Rh*.  Its binding to inactive 
phosphorylated (P-Rh) or active unphosphorylated rhodopsin (R*) is less than 10% of the 
binding to P-Rh*, whereas its binding to inactive unphosphorylated rhodopsin (R) is 
barely detectable (220, 221). A sequential multi-site binding model was proposed to 
explain arrestin-1 selectivity.  This model suggests that arrestin-1 has sensors that 
recognize rhodopsin-attached phosphates and active rhodopsin conformation.  
Simultaneous engagement of both sensors, which only P-Rh* can achieve, triggers a 
global conformational change, allowing arrestin-1 transition into a conformation that 
results in high-affinity receptor-binding (222).  This activation mechanism appears to be 
conserved in the non-visual arrestins (223, 224) that initiate a second round of signaling 
upon receptor binding (126, 225).  Thus, the arrestin-receptor complex serves as a 
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signalosome (126), where the shape of the receptor-bound arrestin apparently determines 
its interactions with multiple signaling proteins (226). 
To obtain a comprehensive picture of receptor-induced conformational changes in 
arrestin-1, we used DEER to perform long-range (~ 17 to 60 Å) measurements of intra-
molecular distances in free and P-Rh* bound arrestin-1.  DEER is a great tool to monitor 
the motion of a protein backbone through interspin distance changes, which can be 
resolved by less than 1 Å difference (227, 228).  In addition, it can provide valuable 
information on multiple conformations and dynamics of proteins from multiple distances 
and the widths of distance distributions.  For these experiments, pairs of R1 nitroxide side 
chains were introduced into arrestin-1, targeting the four loops on the receptor-binding 
surface that were expected to be flexible based on crystal structure.  Additionally, 
multiple positions were targeted in the cores of both domains, where the rigid -strand 
sandwich provides useful reference points.  A total of 25 distances were measured in the 
absence and presence of P-Rh* (Figure 5-1).  The proteins specifically purified or cloned 
by me are detailed in Figure 5-2 and Figure 5-3.  Our data revealed receptor binding-
induced movements of multiple arrestin elements.  The model based on these data is the 
first description of the active receptor-bound arrestin. This structural information will 
improve our understanding of the molecular mechanism of arrestin-mediated regulation 
of GPCR signaling.   
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Figure 5-1.  The 25 interspin distances measured by DEER.   
Ribbon model of arrestin-1 (PDB ID 1CF1, Chain D) (30) composed of two main 
domains (N-, and C- domains in gray and green, respectively).  Inter-domain hinge is 
colored magenta and the finger loop is colored blue.  The very flexible C-tail (red) forms 
a strong intra-molecular interaction with adjacent -helix I (orange) and -strand I 
(yellow), which is crucial for the stability of the inactive state.  Spin-labeled sites are 
shown as blue spheres at their -carbons and black dotted lines represent 25 interspin 
distances measured using DEER. 
 
 
 
 
 
 
 
 
104 
 
 
 
 
Figure 5-2.  139 loop movement pairs.  Cysteines were introduced on cysteine-less base 
background in two positions on arrestin-1.  * Indicate those I purified, the rest are 
mutants I created and cloned. 
 
* 
* 
* 
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Figure 5-3.  Additional cysteine mutants used to measure arrestin movement with 
DEER. * Indicate those I purified, the rest are mutants I created and cloned. 
 
 
 
 
* 
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Materials and Methods 
Preparation of Arrestin Double Mutants and Phosphorylated Rhodopsin 
Site-directed mutagenesis, expression, and purification of arrestin were performed as 
previously described (229).  All mutations were introduced on the fully functional 
cysteine-less base mutant, VSV-CL (C63V, C128S, and C143V) (230).  Rhodopsin in 
ROS membranes was phosphorylated with rhodopsin kinase after illumination and fully 
regenerated by 11-cis-retinal, as previously described (231).  The stoichiometry of 
phosphorylation for the rhodopsin preparations used in this study was higher than 2.5 mol 
phosphates/mol rhodopsin to ensure arrestin-1 binding to P-Rh* (232). 
 
Spin Labeling and Sample Preparation 
For spin labeling, arrestin-1 cysteine mutants in 50 mM MOPS and 100 mM NaCl (pH 
7.2) buffer were mixed with 10-fold molar excess of 1-oxyl-2,2,5,5-tetramethyl-3-
pyrroline-3-methyl methanethiosulfonate spin label (MTSL) overnight at 4 C. Removal 
of excess spin labels and concentration were performed using Amicon Ultra centrifugal 
filter device (Millipore). During concentration, 20% of glycerol was added to the final 
samples as a cryoprotectant.  For receptor-free arrestin samples, the doubly-labeled 
arrestin-1 mutants were mixed with cysteine-less arrestin-1 WT (unlabeled) samples at a 
ratio of 1:3 prior to the concentration in order to get rid of undesired inter-molecular 
distances within the solution tetramer.  For measurements with P-Rh*, two to four molar 
excess of P-Rh in native ROS membranes was pelleted at 100,000 g for 10 min and then 
resuspended in the dark with the doubly-labeled arrestin-1 mutants in the buffer.  P-Rh 
was light-activated by illumination for 2 min at room temperature before the DEER 
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measurement.  Continuous wave EPR spectra were collected for each pair in free and P-
Rh* bound forms to check binding. 
 
DEER Spectroscopy and Data Analysis 
For DEER measurements, 15 L of samples (~ 200 M) were loaded into sealed quartz 
capillaries (1.5 mm i.d.  1.8 mm o.d.) and flash-frozen using liquid nitrogen.  Data were 
collected at 80 K on a Bruker Elexys 580 spectrometer fitted with an MS-2 split ring 
resonator as previously described (231).  Data analysis to obtain distance distribution 
including phase correction, background subtraction, and fitting the dipolar evolution 
function with Tikhonov regularization was performed using the DeerAnalysis 2011 
software (233).  Selected background corrected dipolar evolution data are shown.  In 
order to estimate the median distance, the obtained distance distribution was integrated 
followed by normalization of the integrated plot by maximum amplitude.  The 
normalized integrated plot is useful for estimating relative populations of the distances.  
The median distance was estimated from the midpoint of the transition where the 
population is equally divided into half. 
 
Results 
Introduced pairs of spin labels allowed us to determine three types of distances: 
12 inter-domain, 8 within the N-domain, and 5 within the C-domain.  The distances for 
each pair were measured in free arrestin-1 upon binding to P-Rh* in native disk 
membranes.  Representative distance distribution profiles are shown in Figure 5-4a, from 
which the most probable and median distances were obtained.  Median distances      
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Figure 5-4. The movement of 139 loop of arrestin upon P-Rh* binding is dramatic.  
(A)  DEER data of doubly-labeled arrestin-1 mutants in free (black traces) and P-Rh* 
bound (red traces) states.  Spin-labeled sites are indicated as spheres in the overlaid two 
chains from the crystal structure of arrestin-1 (PDB ID 1CF1, chain A and D).  Due to 
conformational plasticity, the alpha carbon positions of certain residues are different in 
two chains as indicated.  In particular, the finger loop is shown in both extended (chain 
A) and bent (chain D) conformation.  Spin-labeled pairs were designed to look at inter-
domain movement (A) and the conformational changes in four flexible loops on the 
receptor-binding sites (B to E). (B) Two proposed structural models of arrestin-1 
determined by RosettaEPR using DEER distance constraints.  Free (gray) and P-Rh* 
bound (orange) structures are overlaid showing the front view (A) and side view (B).  C 
locations of four residues of interest which are in the flexible loops on the receptor-
binding surface are shown as spheres.  Arrows in (B) indicate the direction of 
conformational change upon binding to P-Rh*. 
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(Table 5-1) were used for modeling to take into account broad distance distributions, 
which reflect the plasticity of the region.  The distances were used as geometric 
constraints to predict the conformations of free and bound arrestin-1using Rosetta EPR 
tool (234, 235). All spin-labeled arrestins retained the ability to bind P-Rh*. 
 
Conformational Changes in Arrestin-1 upon Binding to P-Rh*. 
Despite accumulated indirect evidence for conformational changes in arrestin-1 
upon binding to P-Rh*, the actual movements of specific regions in arrestin-1 were never 
determined experimentally. Therefore, to determine the conformation of receptor-bound 
arrestin-1, we measured 25 inter-spin distances to identify possible movement of the two 
domains, finger loop, and four flexible loops on the receptor-binding surface. 
The N- and C- domains in all arrestins are connected by a 12-residue “hinge” 
(Figure 5-1).  The addition of extra residues to the hinge does not affect P-Rh* binding, 
whereas increasing deletions progressively reduces the ability of arrestin-1 to bind P-Rh* 
(26). This suggests that the transition of arrestin into the active receptor-bound state 
requires an extended hinge. Additionally, strong evidence shows that the concave sides of 
both arrestin domains are engaged by the receptor (230, 236-238).  Arrestins in their 
basal state have relatively large (~70 Å) “wingspan” (30, 217-219), as compared to a 
more compact cytoplasmic tip of the receptor (35~40 Å) in their inactive state (239).   
These data taken together lead to the idea that the domains must move relative to each 
other, closing in on the receptor (the clam-shell model) (222).  However, the  
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 Arrestin
Mutant 
Median distance (Å) 
 Free (d1) + P-Rh* (d2) d2-d1 
1 32/356 15.5 16.5 1 
2 72/173 19 21.5 2.5 
3 72/348 39 37 -2 
4 74/60 22.5 27 4.5 
5 74/139 27 23 -4 
6 74/157 34 40 6 
7 74/173 21.5 24 2.5 
8 74/240 36 37 1 
9 74/344 50 47 -3 
10 85/244 34.5 35.5 1 
11 139/60 39 31 -8 
12 139/173 28 18 -10 
13 139/197 43 55 12 
14 139/227 45.5 49 3.5 
15 139/244 23 35 12 
16 139/251 16 34 18 
17 139/267 41 45 4 
18 139/344 33 44 11 
19 157/173 30 34.5 4.5 
20 173/240 36 33 -3 
21 197/267 27.5 27.5 0 
22 197/344 22 21 -1 
23 244/272 37.5 37 -0.5 
24 244/344 32 25 -7 
25 267/344 21 24.5 3.5 
 
 
 
Table 5-1.  Interspin distances measured using DEER in both free and P-Rh* bound 
arrestin For each pair, two distance profiles were obtained and median distances were 
estimated from them as described in Materials and Methods. 
 
 
 
 
111 
 
measurement of three inter-domain distances revealed only slight changes (<3 Å) upon 
binding to P-Rh* (Figure 5-4a and Table 5-1), which rule out this model.  
In the basal state of arrestin-1, the finger loop is bent towards the N-domain.  We 
investigated possible conformational changes induced by P-Rh* binding, using two 
reference points at positions 72 and 74 (Figure 5-1).  Upon P-Rh* binding the distance 
distribution generally becomes smaller, unless the other site is in a very plastic region 
such as residues 157 and 344, suggesting that the finger loop is near the binding interface 
where the motion is more restricted (Figure 5-4a).  All the pairs with the finger loop show 
distance changes up to 6 Å (Table 5-1), indicating that the finger loop dislocates when in 
complex with P-Rh*.  The best receptor-bound model shows that it moves towards the 
binding interface with P-Rh* (Figure 5-4b).  Interestingly, 7 out of 10 models show a 
propensity of the finger loop to form a-helix upon P-Rh* binding, similar to its helical 
state in free form.   
The most striking movement observed was that of the loop containing residue 139 
(139 loop).  Although this loop is adjacent to the finger loop (Figure 5-1), EPR studies 
revealed that residue 139 is immobilized in the presence of inactive P-Rh.  However in 
contrast to the finger loop, its mobility is dramatically increased in free and P-Rh*-bound 
arrestin-1 (230, 240).  This suggests that 139 loop is not directly involved in P-Rh* 
binding.  Upon P-Rh* binding interspin distances involving position 139 show 
remarkably large changes up to ~20 Å (Figure 5-4a, Table 5-1).  Notably, most of the 
pairs show broad distance distributions both in the absence and presence of P-Rh*, 
indicating that the 139 loop remains flexible in the complex.  This model is consistent 
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with all of the data shows that the 139 loop  moves away from the the receptor-binding 
surface (Figure 5-4b), and is also consistent with previous findings (230). 
 
Discussion 
Light absorption converts rhodopsin into an active form (Rh*), which activates 
visual G protein, transducin (5, 227).  This signaling is switched off by two sequential 
steps: Rh* is phosphorylated by rhodopsin kinase, and then arrestin-1 specifically binds 
to P-Rh*, precluding further G protein activation.  Indirect evidence accumulating for 
more than 20 years suggests that arrestin-1 binding to P-Rh* involves a significant 
conformational change (26, 241-243).  For example, the release of the arrestin C-tail 
upon receptor binding was demonstrated by an increased accessibility of this element in 
the P-Rh*-associated form (242, 243) and higher mobility of C-terminal residues in the 
presence of phosphorylated receptor mimics (244).  However, the first direct proof that 
the C-tail moves away from the -strand I and -helix, with which it interacts in the basal 
conformation (30), was obtained only recently by measuring P-Rh* binding-induced 
changes in distances between the C-tail residues and the body of the molecule using CW 
EPR and DEER (230, 240).  Here we report direct evidence of conformational changes 
accompanying arrestin-1 binding to P-Rh* in other parts of the molecule, using intra-
molecular distance measurements in free and P-Rh*-bound arrestin-1. 
We used 25 different pairs of spin labels to systematically study multiple regions 
in arrestin-1.  In view of strong experimental support for one-to-one arrestin-receptor 
interaction, binding-induced conformational changes in arrestin were expected to make 
the receptor-binding surface more compact, largely by the proposed movement of the two 
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arrestin domains relative to each other (245).  This model was supported by the findings 
that progressive deletions in the inter-domain hinge reduced the ability of all arrestins to 
bind receptors (26, 246).  We detected only subtle changes in the inter-domain distances, 
ruling out large domain movement. Thus, hinge deletions likely perturb site-to-site 
allosteric coupling, which distorts the conformation of arrestin-1 necessary for P-Rh* 
binding (247). Among the four vertebrate subtypes, arrestin-1 shows the highest receptor 
specificity (218, 248) and selectivity for P-Rh* (199).  However, the mechanism of 
arrestin activation by GPCRs is conserved in all subtypes (132, 223, 224), suggesting that 
receptor binding induces similarly small domain movement in non-visual arrestins. This 
would leave a large portion of the molecule essentially unchanged.  This can readily 
explain why many non-receptor signaling proteins bind comparably to free and GPCR-
associated arrestins (20, 39, 47, 132, 249, 250).  
We detected two major rearrangements in the central “crest” on the receptor-
binding side of arrestin-1.  The finger loop was implicated in rhodopsin binding by 
several groups (230, 251, 252).  We found no proof for the predicted transition of the 
finger loop from folded to extended conformation (252): this loop is partially bent in free 
arrestin and moves by less than 5 Å upon binding, bringing it closer to the binding 
interface.  Recently, it has been shown by NMR that an arrestin peptide corresponding to 
the finger loop becomes -helical upon binding to P-Rh* (251).  Restraining this α-helix 
formation by disulfide linkage inhibits arrestin binding to P-Rh*, indicating that the 
conformational flexibility is required for arrestin transition to P-Rh*-bound state. Our 
data showed its tendency to form a helix in both free and bound state.  Interestingly, 
members of three protein families that preferentially bind active GPCRs: G proteins, G-
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protein-coupled receptor kinases (GRKs), and arrestins all show a similar helical 
conformation when bound to GPCRs.  The unstructured C-terminus of the G protein -
subunit interacts with the cavity that opens between the receptor helices upon activation, 
assumes -helical conformation upon binding (253, 254).  Similarly, the unstructured N-
terminus of GRKs implicated in binding active receptor (255, 256) also assumes helical 
conformation as revealed by crystal structure of GRK6 in an active-like state (257).  
Therefore, the N-terminal helix of GRKs was proposed to bind in the same active GPCR 
cavity as the C-terminus of G (257).  If the finger loop of arrestin binds in the same 
cavity, as appears likely based on 1:1 interaction stoichiometry (258, 259) and 
localization of receptor-binding elements on the concave sides of both arrestin domains 
(230, 238, 248, 260), that would mean that all three types of proteins specifically 
recognizing active receptors use flexible loops that fold into an -helix in the binding 
pocket of GPCRs.  
Notably, the pairs involving “139 loop” showed the largest distance change upon 
binding.  Our data are consistent with a dramatic displacement of139 loop, with its tip 
swinging out by ~15 Å, apparently out of the receptor-binding surface. This explains our 
previous finding that residue 139 comes into contact with phosphorylated inactive 
rhodopsin, but reverts to high basal mobility in complex with P-Rh* (230).  Our data 
suggest that the observed large movement of the 139 loop facilitates receptor binding. In 
fact, the deletions in this region increase P-Rh* binding.  Collectively our data suggest 
that 139 loop stabilizes the basal conformation of arrestin-1 and serves as a “brake”, 
preventing its binding to dark P-Rh and Rh*.  This would increase arrestin-1 selectivity 
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for P-Rh*.  This loop is located next to the finger loop, and both are conserved in all 
arrestins, indicative of its biological importance. 
In summary, we present direct evidence of the conformational changes in arrestin-
1 upon binding to P-Rh*.  A model based on our data is the first low-resolution structure 
of the active-receptor bound state of any arrestin (figure 5-4b).  We identified two large 
receptor-induced conformational changes, the release of the C-tail and the movement of 
139 loop.  Additionally we identified the smaller-scale movement of the finger loop and 
several other arrestin elements. Importantly, this is the first demonstration that the 
movement of 139 loop is important for receptor selectivity.  The shape of the receptor-
bound arrestin provides firm structural basis for the mechanistic studies of arrestin-
mediated signaling.  Our data identify arrestin elements that change upon receptor 
binding, which likely determine preferential interactions of receptor-bound or free 
arrestin with certain partners (226).  Disruption of the binding sites for individual partners 
can be used to re-channel arrestin-mediated signaling to desired pathways for therapeutic 
purposes (225).  While the crystal structure of the complex would yield higher resolution, 
EPR and NMR provide dynamic information that cannot be supplied by crystallography, 
which is particularly important for obtaining information about the high plasticity of most 
proteins, including arrestins.  
 
This data chapter was adapted from a manuscript in preparation:  “The conformation of 
the receptor-bound visual” by Miyeon Kim, Sergey A. Vishnivetskiy, Ned Van Eps, 
Whitney M. Cleghorn, Xuanzhi Zhan, Nathan Alexander, Susan M. Hanson, Jens Meiler, 
Vsevolod V. Gurevich, and Wayne L. Hubbell.  
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CHAPTER VI 
 
CONCLUSIONS  
 
Arrestins regulate cell spreading and motility via focal adhesion dynamics 
Arrestins are ubiquitous regulators of cell signaling and are expressed in all cells 
types.  They were first shown to bind and terminate signaling through cognate GPCRs, 
and were later shown to link these receptors to different signaling pathways.   In an 
“unstimulated” state arrestins are fairly diffuse throughout the cytoplasm where they are 
either free or bound to signaling proteins (Figure 6-1) (35, 39, 261, 262).   In addition, 
arrestins are able to bind microtubules at physiological concentrations, but a small 
fraction is also present in the nucleus (39, 122, 263) or anchored to the plasma membrane 
via interactions with other proteins (37).   
One of the key features of arrestin is its ability to translocate to the plasma 
membrane to quench receptor signaling. Arrestins recruitment to GPCRs occurs within 
minutes (264).  They may be recruited to the receptor to terminate G protein signaling 
alone, or may bring one or more signaling proteins already bound to it (Figure 6-1) (39). 
Some arrestin binding partners bind to both receptor-bound and free arrestin, whereas 
some prefer one form to the other (33, 34).  Many studies have described a vast number 
of non-receptor binding partners that are localized by arrestin to receptors such as as 
AP2, clathrin, c-Src, PDE4, ARNO, Arf6, etc., and serves as a scaffold for MAP kinase 
cascades facilitating the activation of JNK3 and ERK1/2 (reviewed in (1, 34, 265)).  The  
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Figure 6-1. The functional cycle of arrestin proteins.  
Left panel. In a cell where most GPCRs are silent arrestin is distributed throughout the 
cytoplasm. Some of the cytoplasmic arrestin is bound to microtubules. The extent of 
nuclear localization depends on arrestin subtype (arrestin2 >> arrestin3) and cell type. 
Free cytoplasmic and nuclear arrestin interacts with several non-receptor binding 
partners: JNK3, Mdm2, and likely many others. Microtubule-bound arrestin mobilizes 
ERK1/2 and Mdm2 to the cytoskeleton. Right panel. Upon stimulation of one or more 
GPCR subtypes a significant proportion of arrestin is mobilized to the receptor(s), so that 
the abundance of free and microtubule-bound arrestin decreases. Receptor-bound arrestin 
serves as an organizer of signalosome, mobilizing numerous signaling proteins to the 
receptor and scaffolding c-Raf-1->MEK1-.ERK1/2 and ASK1->MKK4-.JNK3 MAP 
kinase cascades.   
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number of known non-receptor binding partners of arrestin proteins has been continually 
growing; it exceeded thirty at the last count (1).  
Arrestins were recently shown to bind to microtubules (98).  Binding sites for 
GPCRs and microtubules on the arrestin molecule largely overlap which means that the 
non-receptor binding elements of arrestin are exposed in both cases (266, 267).  Indeed 
we showed that arrestins recruit ERK1/2 and Mdm2 to the microtubules with different 
functional outcomes (100).  First, arrestin brings ERK1/2 to the MTs but not its upstream 
kinases cRaf1 and MEK1.  This results in a decrease in the active levels of ERK in the 
cytoplasm suggesting that arrestins bring ERK1/2 to the microtubules to keep it away 
from compartments of the cell where it can be activated.  Conversely, recruitment of 
Mdm2 to microtubules by arrestin channels Mdm2 activity toward cytoskeleton-
associated proteins, significantly increasing their ubiquitination.  This was the first study 
to show that arrestins interaction with microtubules has a direct functional outcome.  
However the biological relevance of this interaction was still poorly understood. 
We described for the first time a dramatic phenotype of arrestin-2/3 DKO MEFs, 
and demonstrate that arrestins regulate cell morphology by two different mechanisms.  
First, arrestins regulate RhoA to promote proper cell spreading.  Second, arrestins 
regulate focal adhesion activity and disassembly.  
The Rho family of GTPases is comprised of signaling proteins that control cell 
shape by interacting with a variety of different effectors that regulate the cytoskeleton.  
RhoA was previously identified as an arrestin-2 target.  RhoA-induced stress fiber 
formation was shown to be dependent on arrestin-2, but not arrestin-3, following 
activation of the AT1AR receptor (70).  Arrestin-2 was shown to bind RhoGTPase 
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activating protein, ARHGAP21, a known inhibitor of RhoA activity (74).  In both studies 
arrestin knockdown was shown to reduce RhoA activity, similar to what we found in 
arrestin-2/3 DKO cells.  These studies implicate the main function of arrestins regulation 
of RhoA is to promote its activity. However the functional outcomes of this regulation 
were not addressed.  Here we show for the first time that arrestins regulate RhoA activity 
to promote proper cell spreading.  Rescue with a constitutively-active RhoA mutant, but 
not Rac1, returned the cell size back to WT.  Furthermore, reducing RhoA activity in WT 
cells resulted in an increase of cell spreading similar to DKO when plated on poly-D-
lysine. We also show that, both arrestin-2 and arrestin-3 are able to regulate RhoA 
activity independently, and in the absence of receptor activation.  Knock-down of either 
arrestin does not change RhoA activity, however knock-down of both dramatically 
reduces it.  Overexpression of either non-visual arrestin in Hek293a results in similar 
activation of RhoA.  Thus arrestin-2 and arrestin-3 are both able to regulate RhoA 
activation.   
Focal adhesions are key signaling modules that link extracellular stimulus to 
signaling components inside the cell.  The rapid assembly and disassembly of focal 
adhesions is essential for migration and adhesion.  Here we show that arrestin DKO cells 
have a defect in focal adhesion turnover and that rescue with either non-visual arrestin is 
partial.  These data suggest that contrary to arrestins regulation of RhoA, regulation of 
focal adhesion dynamics requires both arrestins. The number and size of focal adhesions 
are dramatically increased in the absence of arrestins, and this number increases over 
time. Importantly, surface integrin levels were also increased in DKO cells and the 
activity of signaling proteins FAK and paxillin were increased.   
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The functional importance of arrestins regulation of small GTPases and focal 
adhesion dynamics became clear when arrestin2/3 knock-down decreased the cells ability 
to migrate nearly 4-fold, however the cells were able to adhere significantly better.   
Interestingly, rescue of the defect in cell migration with either arrestin was also partial, 
suggesting that focal adhesion disassembly is likely the reason. 
 While much is known about how focal adhesions assemble, not much is known 
about how they disassemble.  Some studies implicated that a decrease in RhoA and an 
increase in FAK promotes FA disassembly.  However, our cells have impaired focal 
adhesion disassembly despite both decreased RhoA activity and an increase in FAK 
activity, suggesting that arrestins regulate dynamics upstream of these signaling proteins. 
Recently microtubule targeting has emerged as the predominant mediator of disassembly 
(142, 143).  One key study (153) revealed several facts about this mechanism. First, that 
the Rho family GTPases are not involved. Second, that FA disassembly requires 
microtubules and dynamin, two players not involved in FA assembly.  We showed that 
FAs in DKO cells do not respond to nocodazole treatment: additional FAs do not form 
when microtubules are destroyed, and FA disassembly is abnormal during microtubule 
regrowth in these cells. These data suggest that arrestins, known to bind microtubules 
(100), likely serve as a link between microtubules and FA dynamics.  
 Our data reveal a completely novel function of arrestin proteins. For the first time 
we demonstrate that arrestins regulate the cytoskeleton through two mechanisms.  First 
arrestins regulate small GTPases of Rho family independently of GPCR stimulation to 
promote proper cell spreading. Secondly, we discovered direct arrestin effect on FA 
disassembly, which is not mediated by small GTPases. Thus, here we demonstrate two 
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new arrestin functions that regulate processes involved in cell spreading, adhesion, and 
migration. 
 
Future directions 
Arrestin-dependent internalization is not limited to GPCRs.  Other receptors such 
as insulin-like growth factor I receptor (IGF-IR) are also internalized by arrestins. 
However whether arrestins internalize integrins has never been addressed.  To determine 
this experimentally, integrin internalization in DKO cells should be compared to WT 
using tagged integrin and TIRF microscopy. To determine if this is arrestin specific, 
rescue experiments should be performed with DKO cells expressing either arrestin-2 or 
arrestin-3, or both.  It is expected that if a defect in integrin internalization is the cause of 
the focal adhesion turnover defect, that both arrestin proteins would be required.   
The next step would be to determine the mechanism of arrestin-dependent 
integrin internalization.  Arrestins are capable of binding to AP-2 and clathrin to 
endocytosis GPCRs.  To determine whether the mechanism for integrin internalization is 
similar, the first experiment would be to monitor whether clathrin accumulates at focal 
adhesions during microtubule targeting in DKO cells using live cell TIRF microscopy.  
Additionally, arrestin mutants where clathrin sites have been mutated on arrestin C-tail 
could be infected into DKO cells.  If arrestins recruitment of clathrin is required, integrin 
internalization would still be impaired.  If arrestins promote internalization through 
another mechanism, DKO cells expressing this mutant would internalize like WT. 
To further characterize this mechanism, experiments to determine if other proteins 
that regulate integrin endocytosis are involved in arrestin-dependent focal adhesion 
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disassembly.  FAK has been shown to be required, and we showed that arrestins bind to 
FAK and regulate its activity.  To determine if this interaction promotes disassembly, 
binding sites for FAK on arrestin could be determined, and small peptides used to block 
this interaction. Additionally, it is unknown whether arrestins interact with dynamin or 
clathrin adapter Dab2, both involved in clathrin-mediated integrin internalization.  Co-
immunoprecipitation experiments and subsequent co-localization experiments via TIRF 
could be done.  
To determine whether arrestin-dependent integrin internalization is a result of 
microtubule targeting, first look at surface integrin level by FACs before and during MT-
induced focal adhesion disassembly.  Additionally, experiments could be done to look at 
arrestin/clathrin targeting to focal adhesions during nocodazole washout and microtubule 
regrowth using TIRF microscopy.  Thirdly, determine whether arrestin-Δ7 mutants, with 
enhanced microtubule binding alter dynamics during microtubule regrowth.  And lastly, 
binding elements on arrestin important for microtubule binding have already been 
identified.  Mutations of these residues to determine the most critical can be made to 
render an arrestin protein deficient in microtubule binding. If integrin internalization and 
focal adhesion dynamics are still altered in DKO cells, arrestins likely serve as a link 
between microtubules and focal adhesions. 
It is entirely possible that arrestins regulate focal adhesion dynamics by a 
mechanism not involving direct integrin endocytosis.  First, arrestins bind to FAK, and 
may promote focal adhesion turnover by regulating FAK activity.  Additionally, paxillin 
phosphorylation is also increased in the absence of arrestins.  However, the relationship 
between the activity of these proteins and arrestins has not been addressed.  We show that 
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arrestin-2 binds to FAK, however, the biological importance of this interaction is 
unknown.  Interaction sites on arrestin or FAK important for their binding can be 
determined through EPR, or by mutation of specific residues and subsequent binding 
assays.  Small peptides can be used to block the interaction between the two, and focal 
adhesion disassembly can be monitored. 
Paxillin has been shown to be phosphorylated by a well-known arrestin scaffold: 
the cRaf1-MEK1-ERK1/2 cascade (42, 155).  Localization of ERK1/2 to focal adhesions 
could be mediated by arrestins.  Arrestin-dependent recruitment of ERK1/2 to focal 
adhesions could be monitored experimentally by TIRF.  It is also entirely possible that 
arrestins link paxillin to the ERK cascade and these interactions could be determined 
biochemically. 
 
  
Progressive reduction of its expression in rods reveals two pools of arrestin-1 in the 
outer segment with different roles in photoresponse recovery 
      Comprehensive understanding of systems behavior of rod photoreceptors requires 
precise knowledge of the concentration, localization, and activity of every signaling 
protein in the cell. While the functional role of many signaling proteins in rod 
phototransduction have been qualitatively established using genetically modified mice 
(reviewed in (83)), the biological significance of the specific level of each protein is 
rarely addressed. Here we report an unexpected finding that 20-fold reduction of arrestin-
1 content in the dark-adapted rod OS from 100% to 5% of WT level has no appreciable 
effect on photoresponse recovery, whereas further 2-fold reduction to 2.5% dramatically 
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slows this process. Our data suggest that most of arrestin-1 in the OS of Tr-4
Arr-/-
 animals 
is not immediately available for rhodopsin quenching. 
        In summary, our data suggest the existence of two distinct pools of arrestin-1 in 
dark-adapted mouse outer segments. To the best of our knowledge, so far only one 
genetically modified mouse line where rhodopsin shutoff was made rate-limiting was 
described: mice with low expression of GRK1/2 chimera (215). In Tr-4
Arr-/-
 mice we 
made rhodopsin shutoff the rate-limiting stage of photoresponse recovery by low 
expression of arrestin-1. Collectively, these results strongly support the idea that both 
phosphorylation and arrestin binding are necessary steps in rhodopsin shutoff. 
 
Future Directions 
 One sure way to ascertain whether a proportion of arrestin comparable to the 
concentration of arrestin in the OS of Tr-4
Arr-/-
 mice is localized to microtubules, is to 
look at arrestin localization in these cells in the dark.  Simple immunofluorescence 
experiments staining for arrestin-1 and tubulin would not be informative because the 
concentration of arrestin-1 is undetectable in the OS of these mice. Therefore, arrestin-1 
localization would have to be determined by electron microscopy.   
  
The conformation of receptor bound arrestin 
 We present direct evidence of the conformational changes in arrestin-1 upon 
binding to P-Rh*. We identified two large receptor-induced conformational changes: the 
release of the C-tail, and the movement of 139 loop.  The incredible movement of this 
loop is a completely novel discovery, and sheds light into arrestins selectivity for GPCRs.    
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We also showed smaller-scale movement of the finger loop and several other arrestin 
elements.  A model based on our data is the first low-resolution structure of the active-
receptor bound state of any arrestin.  Our data identify arrestin elements that change upon 
receptor binding, which likely determine preferential interactions of receptor-bound or 
free arrestin with certain partners (226).  While the crystal structure of the complex 
would yield higher resolution, EPR and NMR provide dynamic information that cannot 
be supplied by crystallography, which is particularly important in view of high plasticity 
of most proteins, including arrestins.  
 
Future Directions 
 Arrestins recruitment and binding to GPCRs has many functional outcomes, and 
its conformation is the key determinant of its functional capabilities (33). The flexibility 
of the loops may allow arresitn to assume different conformations, and could explain why 
the non-visual arrestins accommodate hundreds of structurally divers GPCRs.  A better 
understanding of this complex would allow investigators to explore the binding elements 
for both GPCRs and non-receptor bidning partners. Additional studies to better 
understand the dynamic nature of these proteins, and a crystal structure of this complex 
are essential. Knowing exactly how these two proteins interact would allow investigators 
to create mutations in arrestin that affect the flexibility of the molecule and potentially 
limit the conformational space it can inhabit.  In this way, one could alter arrestins ability 
to interact with some partners without affecting the binding to others, thereby 
dramatically shifting arrestin-mediated signaling.  Because arrestins play a role in so 
many different cellular functions, the therapeutic implications of this are vast. 
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Thesis Conclusions 
 Arrestins are diverse signaling molecules that regulate a variety of proteins in the 
cell.  There are four arrestins subtypes, two expressed in the retina, arrestin-1 and 
arrestin-4, and two that are ubiquitously expressed, arrestin-2 and arrestin-3.  While the 
functional requirements of arrestins expressed in the retina vary from the arrestins 
expressed in all cell types, several functions are the same.  First, all arrestins terminate 
GPCR signaling. Second, all arrestins bind to microtubules.  It is my hope that the 
findings in this thesis provide a better global understanding of arrestin signaling at the 
receptor and cytoskeletal level in both visual and non-visual systems.   
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APPENDIX A 
 
 
 
Robust self-association is a common feature of mammalian visual arrestin-1 
 
Much of the work in this chapter was published in Biochemistry in February 2011 (268). 
The paper was a collaborative effort between the laboratories Vsevolod V. Gurevich  and 
Wayne L. Hubbell. 
 
My contribution to this work was purification of human arrestin-1. 
 
Arrestin-1 binds light-activated phosphorhodopsin and ensures rapid signal 
termination. Its deficiency in humans and mice results in prolonged signaling and rod 
degeneration. However, most of the biochemical studies were performed on bovine 
arrestin-1, which was shown to self-associate forming dimers and tetramers, although 
only the monomer binds rhodopsin. It is unclear whether self-association is a property of 
arrestin-1 in all mammals, or a specific feature of bovine protein. To address this issue, 
we compared self-association parameters of purified human and mouse arrestin-1 with 
those of bovine counterpart using multi-angle light scattering. We found that mouse and 
human arrestin-1 also robustly self-associate, existing in monomer-dimer-tetramer 
equilibrium. Interestingly, the combination of dimerization and tetramerization constants 
in these three species is strikingly different. While tetramerization of bovine arrestin-1 is 
highly cooperative, with KD,dim
4
 > KD,tet, in mouse KD,dim ~ KD,tet, whereas in human 
KD,dim << KD,tet. Importantly, in all three species at very high physiological concentrations 
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of arrestin-1 in rod photoreceptors, most of it is predicted to exist in oligomeric form, 
with relatively low concentration of free monomer. Thus, it appears that maintenance of 
low levels of active monomer is the biological role of arrestin-1 self-association. 
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Figure A.  Mouse and human arrestin-1 form dimers and tetramers at physiological 
concentrations.  (A) The average molecular weight of wild type mouse arrestin-1 as a 
function of total concentration (black circles) was determined from the light scattering 
data as described in the Methods. The solid curve is a least-squares fit of the data to the 
MDT model with KD,dim = 57.5±0.6 μM and KD,tet = 63.1±2.6 μM. The data for bovine 
arrestin-1 are shown as squares for comparison. (B) The percentage of mouse arrestin-1 
molecules in monomer (M, straight line), dimer (D, dashed line), and tetramer (T, dotted 
line) as a function of total arrestin-1 concentration computed for the MDT model and the 
data in panel A. (C) The average molecular weight of wild type human arrestin-1 as a 
function of total concentration (black circles) was determined from the light scattering 
data. The solid curve is a least-squares fit of the data to the MDT model with KD,dim = 
2.95±0.02 μM and KD,tet =224±5 μM. (D). The percentage of human arrestin-1 molecules 
in monomer (M, straight line), dimer (D, dashed line), and tetramer (T, dotted line) as a 
function of total arrestin-1 concentration computed for the MDT model and the data in 
panel (C). Vertical lines in (B) and (D) correspond to arrestin-1 concentrations in the 
outer segment (300 μM, black) and cell body (2,000 μM, gray) of dark-adapted rod. 
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Table A-1 
Equilibrium constants characterizing self-association of WT and mutant mouse, human, 
and bovine arrestin-1. 
Protein log Kdim
a
 log Ktet
a
 KD,dim, μM KD,tet, μM 
Mouse arrestin-1 4.24±0.04 4.20±0.17 57.5±0.6 63.1±2.6 
Mouse arrestin-1-(F86A,F198A) 3.27±0.05 - 537±9 - 
Mouse arrestin-1-(F86A,F198A, A349V) 3.14±0.11 - 724±26 - 
Human arrestin-1 5.53±0.03 3.65±0.08 2.95±0.02 224±5 
Bovine arrestin-1 4.43±0.02 5.13±0.03 37.2±0.2 7.4±0.1 
Bovine arrestin-1-(F85A,F197A) 3.28±0.10 - 525±16 - 
a
Kdim and Ktet are the association constants determined from light scattering analysis. 
 
 
 
 
 
Table A-2 
Predicted concentrations of monomer, dimer, and tetramer of mouse, human, and bovine 
arrestin-1 at concentrations in the outer segment (300 μM) and cell body (2,000 μM) of 
dark-adapted rods. 
Arrestin-1 Total, μM Monomer, μM (%) Dimer, μM (%) Tetramer, μM (%) 
Bovine 300 27.6 (9.2%) 20.8 (13.9%) 57.7 (76.9%) 
Mouse 300 52.8 (17.6%) 48.8 (32.5%) 37.4 (49.9%) 
Human 300 15.5 (5.2%) 82.1 (54.7%) 30.1 (40.1%) 
Bovine 2,000 46 (2.3%) 59 (5.9%) 459 (91.8%) 
Mouse 2,000 95 (4.7%) 159 (15.9%) 397 (79.4%) 
Human 2,000 29 (1.5%) 281 (28.1%) 352 (70.4%) 
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APPENDIX B 
 
Caspase-cleaved arrestin-2 and BID cooperatively facilitate cytochrome C release 
and cell death 
 
This work is in review and is a collaboration between the laboratories of Eugenia V. 
Gurevich, Vsevolod V. Gurevich, and Jeffery L. Benovic. 
 
My contribution to this work was caspase inhibition assay to determine caspases 
that cleave arrestin-2, and purification of arrestin2 (1-380) and caspase resistant 
arrestin2-D380/408E for direct study of cytochrome C release from mitochondria. 
 
Arrestins are multi-functional regulators of cell signaling that interact with 
hundreds of G protein-coupled receptors and numerous other proteins. Here we 
demonstrate that arrestin2 is specifically cleaved at Asp380 and Asp408 by caspases 
during apoptosis induced by a variety of stimuli in different cell types. Caspase-generated 
arrestin2(1-380) translocates to mitochondria facilitating cytochrome C release and 
apoptotic cell death. At physiological concentrations, arrestin2(1-380) directly enhances 
cytochrome C release from isolated mitochondria induced by cleaved N/C-BID. In 
contrast, caspase-resistant arrestin2-D380/408E increases cell survival. Arrestin2-
D380/408E does not affect the action of N/C-BID on isolated mitochondria and 
demonstrates strong cytoprotective effect in cells lacking endogenous arrestins, which 
rules out its competition with the fragment. Thus, caspases convert cytoprotective full-
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length arrestin2 into pro-apoptotic arrestin2(1-380) fragment, creating a positive feedback 
loop with a built-in threshold determined by the level of arrestin2 expression in the cell. 
This earlier unappreciated mechanism significantly contributes to the progression of 
apoptosis.  
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Figure B-1. Arrestin-2 is cleaved by specific caspases.  
In etoposide-treated rat-1 cells we found that inhibitors of caspases-4, -8, and -9 reduce 
the accumulation of the arrestin2 fragment, whereas the inhibitors of initiator caspases-2 
and -10 and executioner caspases-3 and -6 do not.  Rat-1 cells were pre-treated with 100 
M of indicated caspase inhibitors for 2 h and exposed to 40M etoposide for 24 h. The 
number below indicates caspase specificity of the inhibitors: PAN, pan-caspase zVAD-
fmk; 1, zWEHD-fmk; 2, zVDVAD-fmk; 3, zDEVD-fmk; 4, zYVAD-fmk; 6, zVEID-
fmk; 8, zIETD-fmk; 9, zLEHD-fmk; 10, z-AEVD-fmk. Upper panel: endogenous 
arrestins were detected with F4C1 antibody and identified by running purified arrestin2, 
arrestin2(1-380), and arrestin3 as standards. The band between arrestin3 and arrestin2(1-
380) present in all lanes is non-specific. Lower panel: GAPDH (loading control). In some 
samples in panels B and C the combined intensity of full-length arrestin2 and its (1-408) 
and (1-380) products is consistently lower than that of arrestin2 band in control, possibly 
due to generation of smaller fragments not detectable by the antibody.   
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Figure B-2. Arrestin2(1-380) binds isolated mitochondria and facilitates cytochrome 
C release induced by caspase-cleaved Bid. (A) Isolated mouse liver mitochondria (20 
g) were incubated in 50 l WHAT buffer with or without 10 nM N/C-Bid and indicated 
concentrations of purified arrestin2(1-380) for 20 min at room temperature. Mitochondria 
were pelleted by centrifugation at 16,000xg for 10 min at 4°C. The distribution of 
cytochrome C, arrestin2(1-380), and COX-IV in the pellet and supernatant is shown. 
COX-IV serves as loading control, as well as control of mitochondria integrity and 
completeness of mitochondria solubilization by Triton X-100. (B) The fraction of 
cytochrome C released by 10 nM N/C-Bid without (0 nM) or with arrestin2(1-380) (50 
and 100 nM) is shown as the percent of the total cytochrome C (released by Triton X-
100). Mean +/- SD of four independent experiments is shown. *, p<0.05; **, p<0.01, as 
compared to 10 nM N/C-Bid alone according to one-way ANOVA with Concentration as 
main factor (F(2,9)=8.84, p=0.0075) followed by Bonferroni/Dunn post hoc comparison.    
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Figure B-3 . Caspase-resistant arrestin2-D380/408E does not affect the integrity of 
isolated mitochondria or cytochrome C release induced by caspase-cleaved Bid. (A) 
Isolated mouse liver mitochondria (20 g) were incubated in 50 l with or without 10 nM 
N/C-Bid and indicated concentrations of purified arrestin2-D380/408E for 20 min at 
room temperature. Mitochondria were pelleted by centrifugation at 16,000xg for 10 min 
at 4°C. The distribution of cytochrome C, arrestin2-D380/408E, and COX-IV in the 
pellet and supernatant is shown. COX-IV serves as loading control, as well as control of 
mitochondria integrity and completeness of mitochondria solubilization by Triton X-100. 
(B) The fraction of released cytochrome C released by 10 nM N/C-Bid without (0 nM) or 
with arrestin2-D380/408E (50 and 100 nM) is shown as the percent of the total 
cytochrome C (released by Triton X-100). Mean +/- SD of four independent experiments 
is shown. N/C-Bid induces the release of ~40% of cytochrome C, and caspase-resistant 
arrestin2-D380/408E does not affect cytochrome C release with (F(2,9)=0.56 p=0.59) or 
without N/C-Bid 
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